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Acute Myeloid Leukemia (AML) is an aggressive cancer that occurs most commonly in 
people over the age of 60. Current treatment comprises intrusive non-specific chemotherapy 
that is often poorly tolerated by patients and frequently leads to other complications. Drug 
redeployment technologies have identified anti-leukemic activity of combined bezafibrate and 
medroxyprogesterone acetate (BaP). BaP induces apoptosis in leukemic cells whilst exerts no 
toxic effect in healthy cells. It has been suggested that the mode of action that BaP undertakes 
to exercise anti-leukemic activity is the disruption of the lipogenic/lipolytic balance needed to 
maintain cell growth and proliferation. 
Western blot and RT-PCR analysis of 24-hour BaP-treated samples were performed across 
myeloid cell lines HL60 and K562, and lymphoma cell lines GLOR and BL31. 
Enzymes important for lipogenesis include ACC and FASN. Levels of the inactive 
phosphorylated-ACC are increased in BaP-treated samples therefore limiting production of 
Malonyl-CoA. Malonyl-CoA is the substrate for FASN which catalyses the final step of 
biogenesis and levels of FASN were shown to be decreased. The product of FASN catalysis 
can be converted into monounsaturated fatty acids via SCDI for the production of 
phospholipids, triglycerides, etc. SCDI expression was reduced in BaP-treated samples 
therefore production of these is likely to be inhibited. Furthermore, lipolysis appears to be 
increased as CPTI levels are increased in BaP-treated samples indicating the 
lipogenic/lipolysis balance is disrupted by BaP. Rescue of BaP-treated samples was possible 
by supplementing with palmitic acid and oleic acid thus suggesting that lipid metabolism is an 





Leukaemia is the term for ‘cancer of the blood’ and relates to a group of associated malignant 
conditions that inhibit the formation of mature healthy white blood cells in the bone marrow. 
This results in the failure of cells to undergo regulated cell death (apoptosis), the uncontrolled 
proliferation of new cells, or a combination of both (Leukaemia and Lymphoma Research, 
2011).  
 
The abnormal survival and accumulation of immature haemopoietic cells in the bone marrow 
(known as blasts) are a result of biological properties of leukemic cells. These include 
decelerated differentiation, deregulation of apoptosis, and ability to spread (Wang and Chen, 
2008), resulting in inhibited production of mature cells.  
 
The disease can be sub-divided into acute or chronic and myeloid or lymphoid. Acute and 
chronic relate to the time frame that the disease exists in. Acute has a short, severe time frame 
with short life expectancy once the disease is contracted, whilst chronic has a longer more 
persistent time frame which allows better control of the disease. See below for statistical life 
expectancy. The disease can be classified as either myeloid or lymphoid depending on blasts 
existing as myeloblasts or lymphoblasts (Hoffbrand et al., 2006). 
 
Chronic Lymphoid Leukaemia (CLL) is a disease where an excess of neoplastic B 
lymphoblasts are produced and occupy the lymphatic system (blood, bone marrow, 
lymphnodes and spleen), interfering with the production of mature lymphocytes (Rozman and 
Monsterrat, 1995). This mass production of lymphoblasts inhibits the body’s ability to deal 
2 
 
with infection and disease and to drain fluid from tissues. The production of lymphoblasts in 
CLL is considered slow and many sufferers can live numerous years without any serious 
symptoms, however in Acute Lymphoid Leukemia (ALL), the production and accumulation 
of lymphoblasts is significantly more rapid causing severe symptoms to occur much sooner 
(Macmillan
a
, accessed February 2014). CLL is often split into stages A, B and C. For patients 
diagnosed in stage A, life expectancy is typically a minimum of 10 years. For patients 
diagnosed in stage B, life expectancy ranges averagely between 5-8 years whilst those 
diagnosed in stage C are expected to live between 1-3 years (Cancer research UK
b
, accessed 
November 2014), for patients suffering from ALL the life expectancy is much shorter with 
only 40% of suffers surviving to 5 years (Cancer research UK
c
, accessed  November 2014). 
 
Chronic Myeloid Leukaemia (CML) is a disease where excess granulocytes are produced. 
Clear phases in the development have been identified through extensive research. ‘Chronic 
phase’ is the initial step, where myeloid progenitor cells (myeloblasts) are present in 
peripheral blood, whilst mature granulocytes are still produced. This is followed by 
‘acceleration phase’ and concluded by ‘blast crisis’ where haematopoietic differentiation has 
stopped and the accumulation of myeloblasts in the bone marrow spills over in to circulation  
(Melo and Barnes, 2007). More than 90% of CML cases are caused by the Philadelphia 
chromosome (Pc)(Kurzrock et al., 2003). The Pc develops when the Abl gene located on 
chromosome 9 is translocated to chromosome 22 and combined with the Bcr gene. The Abl-
Bcr fusion results in the production of tyrosine kinase which leads to blood and bone marrow 
deficiencies characteristic of CML (Macmillan
b
, accessed February 2014). For patients 
suffering from CML, 90% often live for 5 years or more from the onset of the disease 
(Cancer research UK
d




Other related diseases include lymphoma. This blood cancer is specifically a dysfunction of 
the lymphocytes and is divided in to Non-Hodgkin (NHL) and Hodgkin (HL). 
Four out of five cases of lymphoma are NHL (Cancer Research UK
a
, accessed December 
2013); of these, Diffuse Large B – Cell Non-Hodgkin Lymphoma (DLBCL) is the most 
prevalent type accounting for approximately 40% of all cases (Alizadeh et al., 2000). This 
disease causes swelling of the lymph nodes and can spread to organs such as lungs, kidneys 
and bones and is ultimately fatal to 60% of sufferers (Macmillan
c
, accessed December 2013). 
 
Historically, distinction between DLBCL and a more rare type of NHL, Burkitt Lymphoma 
(BL) was largely non-reproducible as both were characterised as mature aggressive B-Cell 
Lymphomas that when left untreated proved fatal within a period of months.  
BL was described as a distinctive entity due to translocations which juxtapose the myc 
oncogene loci and one of three immunoglobulin loci being present in almost all BL, resulting 
in endemic and sporadic cases associated with immunodeficiency or immunosuppression.  
However, confusion arose by the presence of myc translocations in other lymphomas, 
including DLBCL (Hummel et al., 2006). 
More recently, distinction between histology, molecular alterations, prognosis and treatment 
of these lymphomas has become possible. Specifically, DLBCL commonly contains 
translocation t(14;18)(q32;q21), which juxtaposes BCL2 gene to the immunoglobulin heavy 
chain gene enhancer. This translocation is absent in BL. Moreover, translocations involving 
8(q24) are characteristic of BL whilst only present in a subset of DLBCL (Edwards et al., 
2014). BL is described as prevalent in males and can present at all ages, and is often 




1.2 Acute Myeloid Leukaemia 
Acute Myeloid Leukaemia (AML) is an aggressive cancer which causes deficits and loss of 
normal function in erythrocytes (red blood cells), thrombocytes (platelets) and neutrophils 
(most abundant type of white blood cell), and is prevalent in people ages 60+ (Khanim et al., 
2009, Murray et al., 2010).   AML is clinically identified by the presence of >20% blast cells 
in bone marrow and blood (Hoffbrand et al. 2006) and has a rapid onset of symptoms  such as 
infection, bleeding and anaemia which can ultimately be fatal within weeks (Khanim et al., 
2009). 
 
The proliferation of blast cells and decreased number of mature leukocytes results in a 
lowered immune system. The production of blast cells in the bone marrow results in a 
reduction in the production of other cell types causing other diseases such as anaemia and 
low platelet count. The blast cells are in such high numbers in the bone marrow that they 
eventually disseminate and spread in to circulation which can then be detected (Leukaemia 
and Lymphoma Research, 2012). 
 
1.3 Current Treatment 
Current treatment for AML comprises intrusive and non-specific treatments including 
chemotherapy, radiotherapy, and in severe cases blood transfusion. Treatments include 
anthracyclines daunorubicin and adriamycin which exert antiproliferative and cytotoxic 




1.4 Drug Redeployment 
Drug Redeployment, also known as Drug Repurposing or Drug Repositioning, offers an 
alternative to finding new drug treatments.  Where empirical data suggests that a drug yields 
apparent spin-off benefits; above that for which it was originally prescribed; then this offers 
an opportunity for new avenues of treatment to be promoted. Using readily available products 
removes the time and costs associated with the discovery, development and registration 
stages of a new drug (Pessetto et al., Gupta et al.), which takes on average approximately 
13.5 years (Gaulton et al., 2010).  
The redeployment option provides a substance that has been toxicity tested and has proved 
stable and clinically safe for human administration.  This aspect is particularly beneficial in 
the treatment of cancers where conventional treatments of chemotherapy are highly toxic and 
patients require a high degree of care. 
The probability of success is also higher than when developing a brand new drug (Thomson 
Reuters, 2012).  By lowering time and costs it makes the treatment more affordable at the 
application stage and so can be used by poorer countries (Tiziani et al., 2009) but it also 
allows the development of treatments for ‘orphan’ diseases that do not capture the attention 
of larger pharmaceutical companies (Manara et al., 2013, Pessetto et al., 2013) 






Table 1.1: Drug Redeployment Therapies 
Drug Original Use Redeployed Use 
Amphotericin B Fungal Infections Leishmaniasis 
Aspirin Inflammation, pain Antiplatelet 
Bromocriptine Parkinson’s disease Diabetes mellitus 
Finasteride Prostate hyperplasia Hair loss 
Gemcitabine Viral infections Cancer 
Methotrexate Cancer Psoriasis, rheumatoid arthritis 
Minoidill Hypertension Hair loss 
Raloxifene Cancer Osteoporosis 
Thalidomide Morning Sickness Leprosy, multiple myeloma 
Sildenafil Angina Erectile dysfunction, 
pulmonary hypertension 
Table 1.1 adapted fromThomas Reuters, 2012 
The most widely recognised drug redeployment operation was that of thalidomide. This 
particular drug was of great public interest due to causing severe birth defects after being 
prescribed as a treatment for morning sickness. Singhal et al (Singhal et al., 1999) identified 
that thalidomide caused such defects by inhibiting embryonic angiogenesis, and that in 
models thalidomide induced apoptosis in newly formed blood vessels. The paper then went 
on to discuss the key role of angiogenesis and neovascularisation in tumour progression in 
multiple myeloma (MM), thus identifying thalidomide as a potential treatment. Later studies 
supported thalidomide as a treatment for MM, including identifying its ability to cause 
apoptosis in MM cells that are resistant to other treatments such as melphalan and 
doxorubicin, both in vivo and in vitro (Hideshima et al., 2000).  
 
Drug redeployment technologies have identified that the combination of the contraceptive 
drug medroxyprogesterone acetate (MPA) with cholesterol lowering bezafibrate (BEZ); 
denoted as BaP, as having anti-leukemic activity in vivo when using Acute Myeloid 
Leukaemia (AML) cell lines. An important aspect to note about BaP treatment is that unlike 
current treatments it has shown anti-leukemic activity without toxicity (Khanim et al., 2009). 
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Southam et al (unpublished) found that BaP exerts anti-leukemic activity by disrupting de 
novo phospholipid and glycolipid synthesis. The redistribution of incorporating 
13
C-D-
glucose from phospholipids and glycolipids into glycerol 3-phosphate suggests BaP disrupts 
synthesis at the acyl chain-addition stage resulting in higher sensitivity to H2O2-induced lipid 
peroxidation and apoptosis. This suggested that BaP increases endogenous reactive oxygen 
species (ROS) whilst making cells more susceptible to the negative impacts of ROS. BaP 
may also increase fatty acid β-oxidation of saturated fatty acids therefore disrupting 
phospholipid synthesis. Southam et al (unpublished) identified the disruption of cellular 
lipogenic/lipolytic balance as a likely mechanism of anti-leukemic activity exerted by BaP. 
 
1.5 Cancer cell metabolism 
Cellular metabolism controls the production of ATP to provide energy for normal cell 
function, and in cancer cells for rapid division. Metabolism is responsible for the biosynthesis 
of carbohydrates, proteins, lipids and nucleic acids, in addition to the maintenance of the cells 
Redox Status (Cairns et al., 2011). 
A key phenotype shown by cancer cells is the Warburg effect, characterised as a shift towards 
anabolic metabolism under aerobic conditions. ATP production moves from oxidative 
phosphorylation to glycolysis, resulting in high consumption of glucose and producing large 
quantities of lactic acid when under normoxic conditions. The high consumption of glucose 
via glycolysis can provide precursors for DNA/RNA and protein synthesis in addition to 
increased de novo fatty acid synthesis. The glucose via glycolysis can also act as an energy 
supply (Menendez and Lupu, 2007). 
Importantly, the metabolism of cancer cells differs greatly to normal quiescent cells. 
Although ATP production via oxidative phosphorylation is more efficient in terms of ATP 
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production per glucose metabolised, production of ATP via glycolysis is much faster and 
therefore provides energy for proliferation of cancerous cells. Such a shift creates stresses 
within the cells and changes in metabolism are necessary to deal with these.  
For the purpose of this report, lipid metabolism and the Warburg effect shall be focussed 
upon. 
1.5.1 Fatty Acid Synthesis  
Fatty acids are essential for the survival of cells and can be derived exogenously or 
endogenously. Exogenous fatty acids are provided by diet whereas endogenous fatty acids are 
biosynthesised. 
For healthy cells, exogenously derived fatty acids provide a sufficient level of energy, 
therefore reducing endogenous production to a minimum. In these conditions Fatty Acid 
Synthase (FASN) converts excess carbohydrates in to fatty acids which are then esterified 
and stored as triacylglycerols in adipose tissue. These stored triacylglycerols can release fatty 
acids, typically via the influence of lipases, to undergo β-oxidation and provide energy when 













Figure 1.1: Glycolysis, TCA Cycle and Fatty Acid Metabolism 
  
Figure 1.1: Cell metabolism with focus on metabolism of fatty acids as visualised by Southam et al (unpublished). Fatty 
acids are synthesised via the following mechanism; ATP citrate lyase (ACYL) catalyses citrate from the TCA cycle in to 
Acetyl CoA. Acetyl CoA is then converted in to Malonyl CoA via the enzyme Acetyl CoA Carboxylase (ACC). The Acetyl 
CoA and Malonyl CoA are utilised by Fatty Acid Synthase (FASN) to produce the fatty acid, palmitic acid.  
 
 
In cancerous cells however, proteins involved in the up-regulation of endogenous fatty acid 
synthesis have been shown to be accelerated, including fatty acid synthase (Pizer et al., 1996, 
Kuhajda, 2000). Fatty acid synthase (FASN) is a lipogenic enzyme that regulates de novo 
synthesis of fatty acids by catalysing the final stage of biogenesis. An increased level of de 
novo lipogenesis has been associated with many cancers and is a trademark of aggressive 
cancers (Menendez and Lupu, 2007, Louie et al., 2013) including AML. 
 
Another enzyme shown to be up-regulated in cancers is ACC, of which two isoforms have 
been identified (designated α and β or 1 and 2). ACC is a rate limiting step in de novo lipid 




mitochondrial fatty acid β-oxidation by allosteric regulation, and inhibiting Carnitine 
Palmoyltransferase I (CPTI) (see section 1.5.2). The α-isoform has been shown to be up-
regulated in cancer cells and has been linked to increased lipogenesis prevalent in human 
cancers, aiding growth and proliferation of cancer cells (Wang et al., 2010). Whilst both 
isoforms produce Malonyl-CoA, the subcellular location results in ACC-α producing 
Malonyl-CoA for de novo lipogenesis and ACC-β producing Malonyl-CoA for the inhibition 
of CPTI and mitochondrial fatty acid β-oxidation (Jump et al., 2011). Jump et al (2011) 
showed that in cancer cells the use of Soraphen A, a pharmacological inhibitor of ACC 
resulted in reduced de novo lipid synthesis, including synthesis of long chain saturated and 
mono- and poly unsaturated  fatty acids, as well as inducing β-oxidation thus proving ACC to 
play an important role in cancer cell metabolism. 
 
1.5.2 Carnitine Palmitoyltransferase I  
Carnitine Palmitoyltransferase I (CPTI) is an enzyme coded by the gene located at 11q13.2 
and is the rate limiting step in mitochondrial β-oxidation of long chain fatty acids, 
specifically involved in the uptake of these fatty acids into the mitochondria. This enzyme 
catalyses the reaction between long chain fatty acid – acyl CoA conjugates with the 
transporter molecule carnitine. Acyl CoA Synthase modulates the addition of the ‘acyl’ group 
on the fatty acid. CPTI then acts on the resultant fatty acid – acyl CoA conjugate, and 
exchanges the acyl CoA moiety with carnitine forming an acyl-carnitine. The newly formed 
conjugates can then pass through the inner membrane of the mitochondria where the carnitine 
is removed by CPTII and the fatty acid can be metabolised via β-oxidation to produce energy 




Figure 1.2: Carnitine Palmitoyltransferase I Metabolism and Transportation 
 
Figure 1.2: Transportation of fatty acid-acyl CoA occurs by conjugation with transporter molecule carnitine catalysed by 
Carnitine Palmitoyltransferase I. The carnitine allows the movement of acyl-carnitine moiety to pass through the membrane 
with the help of carnitine-acyl-carnitine translocase. Once successfully transported through the membrane and in to the 
mitochondria the carnitine is removed by Carnitine Palmitoyltransferase II leaving the resultant fatty acid available to 
undergo β-oxidation. The carnitine is recycled by the cell. 
 
CPTI is not only regulated by transcription, but also undergoes allosteric modulation and can 
be modified by pH (Morash et al., 2008). 
1.5.3 Stearoyl-CoA Desaturase  
Stearoyl-CoA Desaturase I (SCDI) is a membrane-bound protein located in the endoplasmic 
reticulum. SCDI catalyses the desaturation of saturated fatty acids (SFAs) by introducing a 




Figure 1.3: Steroyl-CoA-Desaturase Mechanism of Action 
 
Figure 1.3: Steroyl CoA Desaturase I catalyses the desaturation of saturated fatty acids by introducing a bond between 
carbons 9 and 10 of acyl-CoAs to produce monounsaturated fatty acids (MUFAs). The MUFAs produced are then used for 
multiple purposes, including synthesis of phospholipids, triglycerides, cholesterol esters, wax esters and 
alkyldiacylglycerols. Modified from (Igal, 2010). 
 
Often the substrates are palmitoyl-CoA (16:0) and stearoyl-CoA (18:0) which are desaturated 
to become palmitoleoyl-CoA (16:1) and oleoyl-CoA (18:1) respectively.  The MUFAs 
produced are then used for multiple purposes, including synthesis of phospholipids, 
triglycerides, cholesterol esters, wax esters and alkyldiacylglycerols . 
Oleic acid is of particular importance in the production of triglycerides and cholesterol esters 
as it is the preferred substrate for the enzymes that catalyse their production: cholesterol 
acyltransfrase and diacylglycerol acyltransferase. Furthermore, oleate is the primary MUFA 
is human adipose tissue and in erythrocyte membranes (Miyazaki and Ntambi, 2003). 
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The importance of MUFAs in the synthesis of lipids means that SCDI plays a key role in 
lipid metabolism. Cancer cells undergo rapid replication and to do so an increased level of 
phospholipids are required, for which MUFAs are also required. Scaglia et al (2009) showed 
that SCDI knockdown reduced the rate of lipid synthesis and of cancer cell proliferation. 
Furthermore, knockdown of SCDI increased the activation of AMPK which is known to 
inhibit ACC. 
1.6 Aims and Objectives 
BaP treatment has been shown to effectively terminate leukemic cells without damaging 
healthy cells, unlike current cancer treatments. Extensive research has shown that lipid 
metabolism plays an essential role in the proliferation of cancer cells and Southam et al 
(unpublished) identified the disruption of lipogenic/lipolytic balance as a potential 
mechanism by which BaP exerts anti-leukemic activity. This research aims to identify 
changes in lipid metabolism of BaP treated cells to investigate the hypothesis proposed by 
Southam et al. To achieve this aim, changes in protein and mRNA levels of key enzymes 
involved in lipogenesis and lipolysis have been explored. A second objective was to assess 
whether providing increased levels of exogenous fatty acids provided changes to lipid 
metabolism, cell survival and cell proliferation in BaP treated samples.
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2. MATERIALS AND METHODS 
2.1 Tissue Cell Culture 
Materials for making Complete Media: 
500ml RPMI 1640 
50ml Foetal Bovine Serum (FBS) 
5ml penicillin/streptomycin 
Method: 
Complete media was made using a base of 500ml RPMI 1640 (ordered from GIBCO, product 
reference 21875). 10% Foetal Bovine Serum (v/v) was added, thus in this instance 50ml, in 
addition to 5ml penicillin/streptomycin (1% v/v/). This was completed inside a fully 
operational fume cupboard with sterile pipettes to avoid contamination. 
An FBS free media was also made using the same method, with the substitution of FBS with 
ITS+ (ordered from Sigma, product reference I2521-5ML). ITS+ is a defined product that 
does not contain the fatty acids considered within this report. 
Materials for culturing HL60, K562, BL31 and GLOR cells: 








Cell lines HL60, K562, BL31 and GLOR mature and multiply most effectively when 
population exists at approximately ¼ million cells per millilitre (ml) of media. From stock 
solutions of the cell lines, the approximate number of cells was calculated using a 
haemocytometer. 
In sterile conditions, 10µl of the cells were inserted on to the haemocytometer and then 
counted using a microscope. From these results it was possible to work out the ratio of the 
current cell line stock to fresh complete media needed to equal approximately ¼ million cells 
per ml to ensure survival and effective growth of the cells. This process occurred every 2 
days to certify the survival of the cell line for use in later testing. 
2.2 Preparation of Palmitate – BSA Solution 
Materials: 
155mM Sodium Chloride (NaCl) in water 
150mM Palmitic Acid in ethanol 
10% Bovine Serum Albumen (BSA) 
Method: 
As described by Kuhajda et al (1996), 155mM NaCl was made by adding 0.45g NaCl to 50ml 
deionised water (dH2O) (0.9% v/v). 
To make 150mM palmitic acid, 38.4mg of palmitic acid should be added to 1ml ethanol. A 
supply of 3ml was made using 116.4mg acid in 3ml ethanol. Due to the nature of palmitic 
acid it does not dissolve readily, however it must be completely in solution before use. The 
mixture was vigorously shaken whilst being held under a stream of hot water until the 
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solution turned clear to be sure the acid was in solution. 
5g BSA was added to the 50ml NaCl solution to make 10% BSA. This was mixed at 37°C 
until completely dissolved. 
1ml 150mM palmitic acid was added to 19ml 10% BSA, and a control set up adding 1ml 
ethanol to 19ml 10% BSA. These were both stirred continuously at 37°C for 1 hour.  Both 
solutions were clear and ready for use by the end of this process. When not in use the stock 
was sterile filtered and frozen as aliquots. 
2.3 Preparation of Bezafibrate (BEZ) and Medroxyprogesterone Acetate (MPA) 
Stock Solutions 
Materials: 
BEZ, molecular weight 362 




Stock solutions were made at 1000 times more concentrated than the desired target value 
when inside the cell culture mix.  
To achieve a 0.5mM concentration of BEZ in the cell culture mix, a stock of 0.5M BEZ was 
created. The following molar equation was used: 
  
 
Therefore to create a 0.5M solution using 181mg/ml, a 4ml stock was made by adding 724mg 






= 0.5 0.5 x 362 = grams 0.5 x 362 = 181g/l > > > 
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A 0.5µM concentration of MPA in cell culture mix was reached via a stock solution of 
0.5mM MPA. The same method of calculation was used for MPA as was used for BEZ, 
therefore utilising 1.935mg/ml, a stock of 10.5ml MPA was produced by adding 20.3g MPA 
to 10.5ml ethanol. 
Particulates occasionally gather at the base of the stock solution and so were heated under a 
hot tap whilst being shaken to ensure all of the MPA and BEZ were in solution prior to use. 
The stocks were stored in a freezer when not in use. 
2.4 Control and BaP Treated Samples 
Four replicates of the following reactions were set up for 24, 48 and 96-hour periods as 
shown in Table 2.1. 
Table 2.1: Composition of Control and BaP Treated Samples 
 Cells in 
Complete 
Media 
Ethanol DMSO BEZ MPA 
Control 8ml 8µl 8µl - - 
BaP Treated 8ml - - 8µl 8µl 
Control + PA 8ml 8µl 8µl   
BaP + PA 8ml - - 8µl 8µl 
 
2.5 Flow Cytometry of K562 and HL60 Treatments 
Materials: 
Annexin V Apoptosis Detection Kit (BD Biosciences, catalogue ref 556547); 
includes 10x Annexin V Binding Buffer, Annexin V and Propidium Iodide 





Approximately 0.5 million cells from each of the above reactions were required for flow 
cytometry, equating to approximately 0.5ml. These were transferred in to labelled tubes and 
2ml PBS was added to each then centrifuged at 1500rpm for 5 minutes.  
A master mix was created using 6ml sterile distilled water, 625µl binding buffer, 62.5µl 
Annexin V and 62.5µl Propidium Iodide. A master mix creates consistency as it allows the 
same mixture to be added to each test. 
Once removed from the centrifuge, the supernatant was discarded from each tube ensuring 
the pellet remained at the bottom. The pellets were then re-suspended in 0.5ml master mix 
and placed in the dark for 15 minutes. This allows the fluorescence markers to bind to the 
markers on the cell surface, in this instance Annexin V will bind to cell markers for 
apoptosis, cells either under-going or that have completed the apoptosis procedure (Annexin 
V), whilst Propidium Iodide identifies non-viable cells, which if not expressing Annexin V 
must have undergone necrosis. 
After 15 minutes in the dark, flow cytometry was performed for each sample using a BD 
FACSCalibur. 
2.6 Western Blot 
2.6.1 Protein Preparation 
100ml RIPA Buffer was made by combining the following in an eppendorf tube; 
1ml [1% v/v] NP40 (IGEPAL)  
0.5g [0.5% w/v] Sodium Deoxycholate 
1ml [0.1%w/v] 10% SDS 
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Up to 100ml ddH2O 
1 x Complete Protease Inhibitor. 






Drug treated and control cells were transferred in to falcon tubes and centrifuged at 1,000rpm 
for 5 minutes. The supernatant was removed and the pellet re-suspended in 1ml PBS and then 
transferred in to a clean eppendorf tube. PBS is isotonic much like the human body and is 
also non-toxic to cells whilst maintaining the cells natural osmotic movement and is therefore 
ideal for cell-washing procedures (Medicago AB, accessed October 2013). The samples were 
centrifuged at 14,000rpm for 10 seconds and 100µl RIPA buffer was added to lyse the cells. 
These were then incubated on a rotator at 4°C for 1 hour. The samples were again centrifuged 
at 14,000rpm at 4°C for 10 minutes to pellet the cell membranes. The supernatant was 
transferred in to clean eppendorf tubes and were stored at -70°C until used. 
2.6.3 Protein Determination using Bio-Rad DC Reagent 
Materials 






Protein standards (0mg/ml, 0.625mg/ml, 1.25mg/ml, 2.5mg/ml, 5mg/ml, 10mg/ml) 
Method 
To determine the level of protein in each sample, the Bio-Rad DC Protein Assay protocol was 
applied. Of each sample and protein standard, 2µl was added to duplicate wells in a 96 well 
plate, thus overall 28 samples were exposed to the determination. To each millilitre of reagent 
A, 20µl reagent S was added and 25µl of this solution was added to each well, followed by 
200µl of reagent B. The samples were agitated for 15 minutes at room temperature to allow 
the reactions to occur before absorbance readings at 645nm were taken. 
From these results a graph was plotted using the protein standards. Using the equation for the 
line of best fit, the amount of protein in the samples could be determined. 
2.6.4 SDS-PAGE Electrophoresis 
SDS-PAGE Electrophoresis was performed to determine protein expression in control and 24 
hour-BaP treated groups of HL60, K562, GLOR and BL31 for the proteins identified 
previously. 
2.6.4.1 Preparing gels for SDS-PAGE Electrophoresis 
A 7.5% gel was used for FASN whilst a 10% gel was used for CPT1A due to the size of each 
protein. FASN is approximately 270kb whilst CPT1A is approximately 76kb. The gels were 







Table 2.2: Composition of Acrylamide Gel 
 Resolving Gel 7.5% Resolving Gel 10% Stacking Gel 
Arcyl/bis 2.5ml 3.3ml 440ul 
4xbuffer 2.5ml 2.5ml 830ul 
10% SDS 0.1ml 0.1ml 33ul 
ddH2O 5.0ml 4.1ml 2.03ml 
10% APS 50ul 50ul 16.7ul 
TEMED 3.3ul 3.3ul 1.7ul 
Table 2.2: Composition of acrylamide gels with quantities relative to making one gel 1.5mm thick 
8ml of resolving gel was poured between glass plates with a gap 1.5mm wide and water was 
layered on top to remove any air bubbles. The gel was allowed to set for approximately 40 
minutes. Once the resolving gel had solidified the water was removed and the stacking gel 
added. A 10-well comb was placed in the stacking gel and more stacking gel was added to fill 
any gaps or air bubbles. This was then allowed to set for approximately 30 minutes to allow 
complete polymerisation. The gels were then secured in a tank with 1 x running buffer ready 
for use. 
Premade 4-15% gradient gels (BioRad) were used to aid separation of larger proteins. 
2.6.4.2 Preparing samples for SDS-PAGE Electrophoresis 
Using information gained from the protein determination, the following calculation was 
performed to determine the amount of each reagent needed to load 20µg of protein in a total 
volume of 20µl in to each well: 
To determine amount of protein sample; 
20µg /protein concentration 
5µl 4 x SDS Gel Loading Buffer (GLB) was added to all samples 
To make the final volume to 20µl, RIPA buffer as described earlier was added. 
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Once the samples were mixed, they were boiled for 10 minutes to ensure complete 
linearization. The combs were removed from the gels and 5µl pre-stained Bio-Rad Precision 
Blue marker was loaded in to the first well, followed by the samples. Electrophoresis was 
performed at 120V until the dye front reached the bottom of the gel. 
2.6.5 Semi-Dry Blotting Transfer 
1 x Transfer buffer was made using 25mM Tris, 192mM glycine and 20% methanol and 
stored at 4°C. PVDF membrane was cut to fit the size of the gel (approx. 8cm by 6cm) and 
soaked in methanol for 5 minutes, whilst 12 pieces of filter paper were soaked in the cold 
transfer buffer. The transfer was set up as below; 
Figure 2.1: Semi-Dry Blotting Transfer 
 
The transfer was run at 25V for 90 minutes. Once complete, the membrane was removed and 
soaked for 3 minutes in Ponceau stain to determine if an equal amount of protein had been 
loaded in each well. The stain was cleared by washing the membrane firstly in ddH2O 
followed by being washed 3 times for 5 minutes in TBS-T (40ml 1.0M Tris HCl pH 7.5, 16g 
NaCl, 20ml Tween 20 and filled to 2L with ddH2O). 
2.6.6 Immunoblotting 
The membranes were washed in TBS-T and then blocked in 5% blotto made up of milk 
powder and TBS-T for 45 minutes. The appropriate dilution of the primary antibody was 
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made in 5% blotto (see Table 2.3) and the membranes incubated in the appropriate antibody 
overnight at 4°C. 
Following this the membranes were washed in TBS-T and incubated in a 1 in 1000 dilution 
of secondary-HRP antibodies in 5% blotto (see Table 2.3). Again, the membranes were 
washed in TBS-T and exposed to 2ml Supersignal West Pico ECL reagent A and B combined 
for 5 minutes. The excess ECL was drained and the membranes were then exposed to film for 
various amounts of time. 
Table 2.3: Volume of primary and secondary antibody added to 10ml 5% blotto 
Antibody (Ab) µl added to 10ml 5% 
blotto 
Mouse Secondary Ab Rabbit Secondary Ab 
FASN 10  X 
CPT1A 10  X 
α-AMP-Kinase 10  X 
Phosphorylated –α-
AMP-Kinase 
10  X 
Acyl-Co-Carboxylase 10  X 
Phosphorylated Acyl-
Co-Carboxylase 
10  X 
SDC1 10 X  
Β-Actin 1 X  
 
Β-actin was used as a loading control, with the membranes being incubated in a 1 in 10,000 dilution 
of the primary antibody for 45 minutes, then washed in TBS-T before being incubated in a 1 in 20,000 
dilution of the secondary Anti-Mouse for a further 45 minutes. The membranes were then re-exposed 
to 2ml Supersignal West Pico ECL reagent A and B combined for 5 minutes and exposed to film. If 






Table 2.4: Antibody Product Information 
Antibody (Ab) Supplier Product Code 
FASN Abcam ab22759 
CPT1A Abcam ab128568 
AMPK and ACC Antibody 
Sampler Kit 
New England Biolabs #9957S 
SDC1 Abcam ab19862 
Β-Actin Sigma Aldrich A5441 
 
2.7 Alamar Blue Viability Test 
The active ingredient of Alamar Blue is Resazurin. This is a non-toxic, cell permeable 
compound that is non-fluorescent, which in the cytosol of viable cells is reduced to a red 
fluorescent resorufin. This reducing activity allows viable cells to fluoresce red therefore an 
overall fluorescence that is more red indicates more live, viable cells (Life Technologies, 
accessed October 2013) 
The following exposures were set-up in a flat-bottomed 96-well plate (6 wells/replicates of 
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2.8 Inhibiting anti-leukemic action of BaP by Fatty Acid Supplementation 
Materials: 
BEZ stock solution 
MPA stock solution 
Ethanol 
DMSO 
K562 cell culture 
ITS+ media (FBS free) 
Method: 
Approximately 26 million cells were obtained in a total of 52ml cell culture to provide a 
supply of 0.25 million cells/ml for each of the reactions shown in Table 2.5. This was 
centrifuged for 5 minutes at 1000rpm at 22°C, after which the supernatant removed and the 
pellet re-suspended in 26ml ITS+ media (fatty acid free) which had been incubated at 37°C. 
Triplicates of the following reactions were set up; 
Table 2.5: Composition of palmitic acid rescue experiments 
 ITS+ 
Media 
Ethanol DMSO BEZ MPA Palmitic 
Acid 
Control 8ml 8µl 8µl - - - 
BaP Treated 8ml - - 8µl 8µl - 
Control + PA 8ml 8µl 8µl   16µl 
BaP + PA 8ml - - 8µl 8µl 16µl 
 
BEZ and MPA were incubated at 37°C and when added to the reaction, the solution was 
gently shaken to ensure maximum incorporation in to the solution. The palmitic acid was also 
incubated at 37°C for 5 minutes prior to use. 
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A reaction using HL60 cells was also set up using 8ml ITS+ media, 8µl BEZ, 8µl MPA and 
16µl palmitic acid. This acts as a control as this reaction showed a positive result in previous 
experiments performed by Southam et al (unpublished). Alamar Blue viability test was 
undertaken as previously described to determine cell viability. 
2.9 Real-Time PCR 
2.9.1 RNA Extraction 
24-hour control and BaP treatments were set up for GLOR and BL31 cell lines so that a total 
of approximately 5 million cells were present at the time of extraction. 
The cells were centrifuged at 1000rpm for 5 minutes, the supernatant was removed and the 
pellet re-suspended in 1ml PBS. Following this the Qiagen RNeasy protocol for RNA 
extraction was performed as follows; 
600µl RLT buffer was added to the sample followed by vortexing to disrupt the cells. The 
lysate was pipetted directly in to a QIAShredder spin column placed in a 2ml collection tube 
and centrifuged at 14,000rpm for 2 minutes. 600µl of 70% ethanol was then mixed with the 
homogenised lysate and 700µl was transferred in to an RNeasy spin column placed in a 2ml 
collection tube.This as centrifuged for 15s at 10,000rpm and the flow-through discarded. 
The spin column membrane was washed by adding 350µl Buffer RW1 and centrifuging at 
10,000rpm for 15s. The flow-through was discarded. DNase I incubation mix was made by 
adding 10µl DNase I stock solution to 70µl Buffer RDD. 80µl of this mix was added directly 
on to the spin column membrane and left to stand at room temperature for 15min. The 
membrane was then again washed by adding 350µl Buffer RW1 and centrifuging at 
10,000rpm for 15s. 
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500µl Buffer RPE was added to the spin column and centrifuged for 15s, followed by adding 
another 500µl to the column and centrifuging for 2min at 10,000rpm and the flow-through 
discarded. To ensure any residual Buffer RPE or flow-through is eliminated, the collection 
tube wash changed and the spin column centrifuged at 10,000rpm for 1 min. 
The RNeasy spin column was then transferred in to a new collection tube and 50µl RNase 
free water was added to the column membrane. RNA was eluted by centrifuging at 
10,000rpm for 1 min. The supernatant was transferred back on to the column membrane and 
centrifuged again to ensure as much RNA had been eluted. 
Levels of RNA were determined by applying 1µl to a nanophotometer. The RNA was stored 
at -80°C until used. 
2.9.2 cDNA Synthesis 
A master mix containing 0.5µl random primers and 1µl 10µM dNTPs for each sample was 
made. 10.5µl ddH2O and 1.5µl master mix were added to 3µg of each RNA extraction. The 
samples were mixed well and heated to 65°C for 6 minutes before being placed on ice for 10 
minutes. Whilst on ice, 8µl of a second master mix (4µl 5x first strand buffer, 2µl 0.1M DTT, 
1µl Rnaseri plus, 1µl Superscrit II per sample) was added to each sample. The samples then 
underwent PCR amplification. 
2.9.3 β-actin PCR 
β-actin was used as means of identifying the production of cDNA from the PCR process. The 
following PCR reactions were set up; 
5µl 10x Buffer 
1.5µl 50mM MgCl2 
1µl 10mM dNTPs 
1µl 10µM β-actin primer mix 
29 
 
0.75µl Biotaq Red 
39.75µl ddH2O 
1µl cDNA (1 in 10 dilution) 
Once mixed, these samples underwent PCR amplification in addition to a negative control. 
20µl 5x DNA loading buffer was added to each of the resultant PCR products and were run 
on a 1% agarose gel at 120V for approx. 90 min. 
2.9.4 cDNA Real-Time PCR 
A master mix was created containing 10µl Low ROX Sensimix, 2µl 10 x primers for protein 
of interest and 6µl dH2O for each sample. 18µmaster mix was added to 2µl diluted cDNA in 
a 96-well PCR plate. The plate was sealed, centrifuged for 3 minutes followed by Real-Time 
measurements. 













3.1 BaP Treatment induces Apoptosis in Leukemic Cell Lines 
 
Figure 3.1: Apoptosis in Control and BaP Treated Samples 
 
Figure 3.1: BaP has potent anti-leukemic activity across a short time-frame in HL60 and K562 cell lines. Control samples 
were treated with DMSO and ethanol in replacement for BaP treatment where 0.5mM Bezafibrate in DMSO and 0.5µM 
Medrozxyprogesterone Acetate in ethanol were added. Four replicates of each underwent Annexin V-Propidium Iodide (AV-
PI) treatment as described and 10,000 cells counted using FACSCalibur. FACS monitored the number of cells expressing 
AV (apoptotic), PI (necrotic) and neither (viable). The above graph represents the average number of cells expressing AV 
from all four replicates after 48 hour and 96 hour treatment. 
After 48-hour treatment, cell viability in BaP treated samples was decreased by >50% of 
control samples in both HL60 and K562 cell lines. After 96-hourtreatment cell viability for 

































Figure 3.2 Annexin V and Propidium Iodide expression in 96-hour treated samples 
      
        
Figure 3.2: A: FACSCalibur data of 96-hour HL60 Control sample (treated with DMSO and ethanol only) (C1). B: 
FACSCalibur data of 96-hour HL60 BaP treated sample (D1). C: FACSCalibur data of 96-hour K562 Control sample 
(treated with DMSO and ethanol only) (C1). D: FACSCalibur data of 96-hour K562 BaP treated sample (D1). Lower left 
fraction represents viable cells, lower right represents cells undergoing apoptosis, upper right visualises cells that have 
undergone apoptosis and upper left represents cells expressing PI without AV therefore cells that have undergone necrosis. 
Further 96-hour AV and Pi FACS data can be found in Appendix I in addition to forward scatter and side scatter data. 
HL60 and K562 control samples represented by Figure 3.2 A and C show a dense cluster of 
cells in the lower left bracket. The dense cluster represents viable cells as they do not express 
Annexin V or Propidium Iodide. In the respective drug treated samples, B and D, the cluster 
of viable cells is dispersed and increased levels of cells in the lower right fraction 






Figure 3.3: Forward Scatter and Side Scatter Data of 96-hour treated samples 
    
     
Figure 3.3: A: FACSCalibur data of 96-hour HL60 Control sample (treated with DMSO and ethanol only) (Control 
Replicate 1). B: FACSCalibur data of 96-hour HL60 BaP treated sample (Drug Treated Replicate 1). C: FACSCalibur data 
of 96-hour K562 Control sample (treated with DMSO and ethanol only) (Control Replicate 1). D: FACSCalibur data of 96-
hour K562 BaP treated sample (Drug Treated Replicate 1). The changes in forward and side scatter recorded between control 
and drug treated samples represents the change s in cell physiology most likely due to the morphological changes that have 
occurred in the drug treated samples after an increased number of cells having undergone apoptosis. For forward and side 
scatter data of a further three replicates of control and drug treated samples for both cells see Appendix I. 
HL60 and K562 control samples, represented by Figure 3.3 A and C respectively, identify a 
high number of cells falling within a close range of forward and side scatter showing cells to 
be of a similar shape. Figure 3.3 B and D represent drug treated samples and show fewer 
areas of high density and the pattern of forward and side scatter is far more dispersed 
identifying cells of irregular shape, supporting the notion of higher levels of apoptosis present 






3.2 BaP alters expression of proteins involved in up-regulation of fatty acid 
synthesis in leukemic cell lines 
 
Figure 3.3: Fatty Acid Synthase Western Blot Results 
                 
Figure 3.3: Western blot results obtained for GLOR, K562 and HL60 cell lines for levels of enzyme Fatty Acid Synthase 
(FASN). Western blots shown were run on a 4-15% pre-made gradient gel (Bio-Rad) and exposed to gel electrophoresis at 
120V for 140 minutes. Protein was transferred from the gel on to PVDF membrane at 25V for 90 minutes. Lanes labelled C 
1-4 represent 4 replicates of control samples treated with DMSO and ethanol only. Lanes labelled D 1-4 represent 4 
replicates of cells treated with 0.5mM Bezafibrate in DMSO and 0.5µM Medrozxyprogesterone in ethanol. 
Western blot analysis identified a decreased expression of FASN in drug treated samples 
compared to control samples (where n=4) in GLOR and K562 cell lines. Although the 
decrease appears small and image J analysis gave p values of 0.222 (GLOR) and 0.07 (K562) 
(see Figure 3.8 for image J analysis results), a trend can clearly be seen across all 4 replicates 
of control and drug treated samples in both cell lines. β-actin has been used as a loading 
control and shows an even level of sample protein was loaded in to each well. No significant 








Figure 3.4: Acetyl-CoA-Carboxylase (ACC) and Phosphorylated-ACC Western Blot Results 
 
Figure 3.4: Acetyl-CoA-Carboxylase (ACC) and phosphorylated-ACC western blot results obtained for K562. Western 
blots shown were run on a 4-15% pre-made gradient gel (Bio-Rad) and exposed to gel electrophoresis at 120V for 140 
minutes. Protein was transferred from the gel on to PVDF membrane at 25V for 90 minutes. Lanes labelled C 1-4 represent 4 
replicates of control samples treated with DMSO and ethanol only. Lanes labelled D 1-4 represent 4 replicates of cells 
treated with 0.5mM Bezafibrate in DMSO and 0.5µM Medrozxyprogesterone in ethanol. 
Western blot analysis showed the presence of total ACC in both control and drug treated 
samples to be fairly consistent after 24-hour treatment, with a p-value of 0.54 suggesting no 
significant change had occurred. Phosphorylated-ACC is clearly present at lower levels in 
control groups and at higher levels in drug treated samples at the 24-hour time point. ACC-α 
has a molecular mass of 245kDa whilst ACC-β has a mass of 280kDa causing a large spot to 
appear on the western blot as opposed to a thin band. β-actin has been used as a loading 











Figure 3.5: Carnitine Palmitoyltransferase IA Western Blot Results 
 
Figure 3.5: Carnitine Palmitoyl Transferase IA (CPTIA) western blot results obtained for GLOR and K562. Western blots 
shown were run on a 4-15% pre-made gradient gel (Bio-Rad) and exposed to gel electrophoresis at 120V for 140 minutes. 
Protein was transferred from the gel on to PVDF membrane at 25V for 90 minutes. Lanes labelled C 1-4 represent 4 
replicates of control samples treated with DMSO and ethanol only. Lanes labelled D 1-4 represent 4 replicates of cells 
treated with 0.5mM Bezafibrate in DMSO and 0.5µM Medrozxyprogesterone in ethanol. 
BaP treated GLOR cells show increased levels of CPTIA when compared to control groups 
after 24-hour treatment. At the same time point, K562 shows partial evidence of the same 
pattern at the expected size of CPTIA (75kDa), but also shows bands at 250kDa that may be a 
trimer of CPTIA at increased levels in drug treated samples. β-actin has been used as a 
loading control and shows an even level of sample protein was loaded in to each well. 
Figure 3.6: Total AMP-Kinase Western Blot Results 
 
Figure 3.6: Total AMP-Kinase western blot results obtained for K562. Western blots shown were run on a 4-15% pre-made 
gradient gel (Bio-Rad) and exposed to gel electrophoresis at 120V for 140 minutes. Protein was transferred from the gel on 
to PVDF membrane at 25V for 90 minutes. Lanes labelled C 1-4 represent 4 replicates of control samples treated with 
DMSO and ethanol only. Lanes labelled D 1-4 represent 4 replicates of cells treated with 0.5mM Bezafibrate in DMSO and 
0.5µM Medrozxyprogesterone in ethanol. 
Levels of total AMP-Kinase appears unchanged between control and drug treated samples 
after 24-hour exposure across 4 replicates. β-actin has been used as a loading control and 




Figure 3.7: Steroyl-CoA Desaturase I Western Blot Results 
 
Figure 3.7: Steroyl-CoA Desaturase I (SCDI) western blot results obtained for GLOR and HL60 cell lines. Western blots 
shown were run on a 4-15% pre-made gradient gel (Bio-Rad) and exposed to gel electrophoresis at 120V for 140 minutes. 
Protein was transferred from the gel on to PVDF membrane at 25V for 90 minutes. Lanes labelled C 1-4 represent 4 
replicates of control samples treated with DMSO and ethanol only. Lanes labelled D 1-4 represent 4 replicates of cells 
treated with 0.5mM Bezafibrate in DMSO and 0.5µM Medrozxyprogesterone in ethanol. 
SCDI is down regulated in BaP treated samples when compared to control groups in cell lines 
GLOR and HL60. β-actin has been used as a loading control and shows an even level of 




Figure 3.8: Western Blot Densitometry Significance Analysis 
 
Figure 3.8: ImageJ software was used to apply densitometry analysis to western blots. Once the density of the band was 
obtained, result were normalised to the density of corresponding β-actin bands that act as a loading control for the well. A 
paired T-Test provided significance values for control-drug pairs. 
*Western blot analysis showed a band at 250kDa for K562, CPTIA. This is potentially a trimer and the pattern shown by the 
trimer was consistent with what would be expected of CPTIA therefore ImageJ analysis was also performed for these bands. 
Densitometry analysis using ImageJ software indicates the change in levels of CPT1A and  



































Figure 3.9: Fold Change between Control and BaP treated samples (Western Blot) 
 
Figure 3.9: Fold change between control and drug-treated samples were calculated by using densitometry results. 
*Western blot analysis showed a band at 250kDa for K562, CPTIA. This is potentially a trimer and the pattern shown by the 
trimer was consistent with what would be expected of CPTIA therefore fold change analysis was also performed for these 
bands. Fold change for the trimer identified a fold change of 0.67. 
Fold-change is a method of quantifying the level of change in the drug treated sample from 
the control group, thus the control group fold-change is a baseline value and therefore is 
represented as 1. Fold-change ranges between 0.50 and 2.03, with the majority of enzymes 
across all cell lines showing a fold-change between 0.90 and 1.50 for drug treated samples. 
For enzymes showing approximately 0.90 fold-change, for example Total-ACC (0.93), this 
represents a negligible change on the drug treated sample. At the upper limit, a two-fold 
change in SCDI levels can be observed in HL60 cell line, whilst at the lower limit a fold-










































Figure 3.10: RT-PCR Analysis 
 
Figure 3.10:  Quantitative Real-Time analysis of mRNA from 24-hour control and BaP treated samples for cells lines BL31 
and GLOR for key enzymes involved in fatty acid synthesis. Results were normalised to 18S ribosomal RNA.  
Fold-change of the RNA levels of the enzymes of interest in drug treated samples ranges 
between 0.39 and 3.04 across all cell lines when analysed via RT-PCR. RT-PCR analysis 
identified a significant increase in RNA levels of CPTIA and ACYL in BaP treated samples 








































3.3 Palmitic Acid provides partial rescue to BaP treated cells 
 
Figure 3.11: Palmitic Acid Rescue Data 
 
Figure 3.3.11: 100mM palmitic acid provided rescue to BaP treated HL60 cells after 48-hour treatment. Control and BaP 
treated samples were set up in a 96-well plate and 0mM, 100mM, 200mM and 300mM palmitic acid were added to 6 wells 
each. Alamar Blue was added to the wells and fluorescence was read at 630nm excitation and 690nm emission. Results were 
analysed and expressed as a percentage of the control group exposed to 0mM palmitic acid. For palmitic acid rescue data of 
other cell lines see Appendix I. 
Cell viability was determined by calculating the percentage of each sample group treated with 
the stated concentrations of palmitic acid, in comparison to a control group treated with 0mM 
palmitic acid.  Drug treated samples treated with 100mM palmitic acid showed 93.01% 
rescue  when compared to the control sample treated with 0mM palmitic acid, however when 
compared to the control sample similarly treated with 100mM palmitic acid the results are 
almost indistinct (control 94.06%, drug-treated 93.01%).  In contrast, higher doses decreased 
cell viability, for example at 300mM treatment cell viability was reduced to 40% of the 0mM 
































3.4 Palmitic Acid plus Oleic Acid provides better rescue than palmitic acid alone 
 
Figure 3.12: Palmitic Acid and Oleic Acid Rescue Data 
 
        
       
 
Figure 3.12: A: BL31. B: GLOR. C: HL60. D: K562. Control and BaP treated samples were set up in a 96-well plate and 
0mM Fatty Acids, 25mM PA, 25mM OA and 25mM PA plus OA were added. Alamar Blue was added to the wells and 
fluorescence was read at 630nm excitation and 690nm emission. Results were analysed and expressed as a percentage of the 
control group exposed to 0mM Fatty Acid. This research was undertaken by Southam et al (unpublished). 
Combined Palmitic acid (PA) and Oleic acid (OA) provided clear rescue to BaP-treated cells 
after 120-hour treatment for BL31 and GLOR cell lines. The combined agents appear to 
provide only a slight improved rescue result for HL60 and K562 cell lines than OA alone, 
however. Cell viability was increased to between 70-100% in BaP treated samples when 
supplemented with both acid agents, with GLOR showing 70% rescue whilst HL60 showed 
100% viability. Palmitic acid alone provided variable rescue, between 40-90% whilst oleic 






































































































4.1 Combined Bezafibrate and Medroxyprogesterone Acetate have potent anti-
leukemic action in leukemic cell lines 
The combination of 5mM Bezafibrate and 5µM Medroxyprogesterone acetate (BaP) when 
added to leukemic cell lines clearly induces apoptosis, as shown by Figures 3.1 and 3.2. After 
48-hour treatment, cell viability in BaP treated samples was decreased by >50% of control 
samples in both HL60 and K562 cell lines. After 96-hourtreatment cell viability for HL60 
had declined to 40%, whilst K562 had been reduced to approximately 33% of control 
samples. Similar results were observed by Khanim et al (2009) which also showed that after 
10 days of BaP treatment a complete loss of cell viability had almost been achieved. 
HL60 is defined as a ‘leukemic-like’ cell line and is an immortalised line derived from a 
patient with acute promyelocytic leukaemia (Collins, 1987). Its characteristics are distinctive 
of myeloid cells and so act as an ideal model for primary drug response research for AML 
treatment. 
K562 is derived from pleural fluid of a chronic myeloid leukaemia patient in blast crisis 
(Collins et al., 1977). Although derived from a patient with chronic leukaemia K562 
expresses myeloid characteristics, therefore the response to BaP treatment is indicative of 
how AML patients may respond to BaP treatment. 
Furthermore, BaP has been shown to exert potent effects in Burkitts-Lymphoma cell lines, 
GLOR and BL31 (data not shown). The anti-leukemic activity of BaP across AML, CML and 
lymphoid leukemic cell lines suggests the pathway BaP is affecting is important for cancer 
cell survival and proliferation and is not just specific to AML. 
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4.2 BaP reduces cell proliferation by inhibiting fatty acid synthesis 
It is widely accepted that fatty acid synthesis is important for the proliferation of cancer cells. 
There are many steps involved in the production and metabolism of fatty acids utilising many 
enzymes, as denoted by Figure 1.1. Western blots were performed using protein extracted 
from 24-hour control and drug treated samples as described in Section 2 and changes in the 
fatty acid synthesis pathway were identified in drug treated samples compared to control 
samples. 
4.2.1 BaP down-regulates Fatty Acid Synthase (FASN) 
Western blot analysis identified a decreased expression of FASN in drug treated samples 
compared to control samples (where n=4). Although the decrease appears small and image J 
analysis gave p values of 0.222 (GLOR) and 0.420 (K562), a trend can clearly be seen across 
all 4 replicates of control and drug treated samples in both cell lines.  
Western blot is an important method for the separation and identification of a particular 
protein from a mixture of proteins, however data analysis of western blots is considered semi-
quantitative due to variation in loading and transfer rates (Mahmood and Yang, 2012). This 
variation is partially mitigated by using a loading control, in this instance β-actin, to identify 
if changes observed between samples are representative of changes in the protein levels, or if 
it is simply due to variable loading. However, the analysis still represents a relative 
comparison between samples but cannot provide absolute quantification. What appears to be 
a small change on western blot analysis could have a far greater significance on a molecular 
level. Therefore an additional analytical method of Real-Time PCR (RT-PCR) was used to 
gain discriminatory evidence. 
RT-PCR analysis of GLOR and BL31 identified a >50% and approx.40% decrease in FASN 
expression in BaP treated samples compared to control groups respectively at 24-hours 
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(Figure 3.4A). Additionally, RT-PCR data collected by Southam et al (unpublished) 
identified a significant decrease in FASN expression in 24-hour BaP treated HL60 cells when 
compared to control cells, however, RT-PCR data for K562 did not show much change at the 
24-hour period.  
The combination of western blot results and RT-PCR data strongly indicates FASN 
expression is down in all cell lines; however additional replicates of RT-PCR analysis for 
K562 and western blot analysis of 24-hour HL60 and BL31 samples could be undertaken to 
complete the data set and provide clarity. Furthermore, a later time point, for example 48-
hour and 72-hour samples, could be analysed using the same methods to determine if the 
changes become greater and therefore more significant at this point. 
As previously described, FASN is responsible for the regulation of de novo fatty acid 
synthesis by catalysing the final stage of biogenesis. BaP inhibits this mechanism by reducing 
FASN expression resulting in the cells inability to synthesise large quantities of fatty acids 
required by the cancer cells to survive and proliferate.  
4.2.2 BaP inhibits ACC by increasing ACC phosphorylation 
Western blot densitometry analysis showed the presence of total ACC in both control and 
drug treated samples to be fairly consistent, with a p-value of 0.54 (K562) suggesting no 
significant change had occurred. ACC-α has a molecular mass of 245kDa whilst ACC-β has a 
mass of 280kDa causing a large spot to appear on the western blot as opposed to a thin band. 
Additionally, a fold-change value of 0.928 was calculated showing little deviation from the 
control value of 1, again suggesting no significant change between control and drug-treated 
samples. Research has shown ACC-α to be slightly up-regulated in cancer cells (Morash et 
al., 2008)  and so may account for slightly higher values obtained for some of the control 
groups, however over all little difference was observed.  
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Notably, there was an increase of phosphorylated-ACC (P-ACC) in BaP treated samples 
(Figure 3.4), with very little shown to be present in control samples. An anti-log fold-change 
value of 0.498 represents the doubled level of P-ACC in BaP treated samples compared to 
control samples. Phosphorylation is a post-translation modification used to regulate gene-
expression and in this instance causes the ACC gene to become inactive. Active ACC is vital 
for the production of the fatty acid substrate Malonyl-CoA. The phosphorylation of ACC and 
consequent silencing of the gene results in a decrease in the production of Malonyl-CoA and 
therefore reduces production of fatty acids without which the cancer cells cannot survive. 
AMPK is activated via phosphorylation in response to cellular metabolic stresses 
(GeneCards, accessed February 2014). Once active, AMPK inhibits ACC via inducing 
phosphorylation, therefore it is reasonable to expect phosphorylated-AMPK to also be up-
regulated in BaP treated samples. Western blot analysis has shown the total AMPK (inactive) 
expression to be fairly consistent across control and drug treated samples, however 
phosphorylated-AMPK (active) data was not obtained. It is unknown if this was due to the 
anti-body batch being faulty or if it was due to the levels of phosphorylated-AMPK in all cell 
lines being too low to be detected thus a positive control test needs to be undertaken. The 
positive control to determine if the phosphorylated-AMPK antibody is working is to pre-treat 
cells with hydrogen peroxide for 1 hour before extraction (extraction method as described in 
Section 2). The hydrogen peroxide causes increased levels of reactive oxygen species (ROS) 
inside the cell which stimulates the activation of AMPK (Zmijewski et al., 2010). This test 
would need to be undertaken to validate the apparent negative result observed. 
RT-PCR data was obtained for ACC-α and ACC-β however the information obtained was 
insufficiently discriminatory to provide an unambiguous correlation. This may be due to 
variability in loading the wells. It would therefore be beneficial to repeat this experiment to 
clarify if this was due to any error in the process. Although the western blot analysis shows 
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little change between control and drug treated samples of total ACC, changes in the level of 
each isoform are not clear (if present) and so a more sensitive analysis approach could 
provide greater differentiation. Each isoform is responsible for different modes of action as 
described in Section 1.5.1, hence if RT-PCR data showed significant change between control 
and drug treated of one isoform but negligible change in another for example, it could 
provide more detail in to how BaP treatment effectively kills leukemic cells. 
4.2.3 BaP up-regulates Carnitine Palmitoyltransferase I (CPTI) 
CPTIA is significantly higher in 24-hour BaP treated samples when compared to control 
groups, with densitometry analysis identifying a significant change between control and BaP 
treated groups in GLOR cell line (significance value 0.012). Western blot analysis proved 
this for K562 and GLOR cell lines (Figure 3.5), whilst RT-PCR data supports this for GLOR 
and BL31 (Figure 3.10). Additionally, K562 western blot analysis showed a consistent 
pattern for what appears to be a trimer of CPTIA (Figure 3.5). CPTI is a membrane-bound 
protein and research has shown that these can form conjugates when heated. Samples were 
boiled for 10 minutes prior to loading which may have caused these trimers to form. To 
reduce the likelihood of polymers forming, β-mercaptoethanol needed to be added to the 
loading dye. 
ACC-β produces Malonyl-CoA that is inhibitory to CPTI (Jump et al., 2011). Western data 
showed high levels of inactive ACC in BaP treated samples therefore inhibitory action of 
Malonyl-CoA on CPTI had decreased, however western data is not exemplary of enzyme 
activity but represents the quantity of protein present. A feedback loop is believed to exist 
between ACC and CPTI whereby a decrease in ACC results in an increase in oxidation 
(Lopaschuk and Gamble, 1994) for which an increase of CPTI may be required to transfer 




When levels of Malonyl-CoA rise, allosteric inhibition of CPTI occurs reducing the rate of 
fatty acid oxidation, instead directing them toward production of triglycerides which are then 
stored as adipose tissue. When levels of Malonyl-CoA decrease, synthesis of fatty acids 
decreases and levels of CPTI rise (McGarry and Brown, 1997) which is likely to be a 
homeostatic mechanism.  
As previously mentioned, CPTI is also regulated via transcription. The transcription factor 
peroxisome proliferated-activated receptor (PPAR), in this case PPARα, regulates gene 
expression and is thought to modulate mRNA in CPTI due to the presence of PPAR response 
elements (Morash et al, 2008). Fibrates have been identified as PPAR ligands(Michalik and 
Wahli, 2006) and cause an increase in the transcriptional activity of PPARα (Inoue et al., 
2002) therefore it is likely that the use of BEZ in BaP influences the increase in CPTI levels 
identified via western blot and RT-PCR analysis. However, Southam et al (unpublished) 
determined that optimal anti-leukemic activity of BaP utilised BEZ (and MPA) at much 
higher concentrations than those used for their initial purpose; therefore suggestive of 
additional mechanisms exerted by BaP being ultimately responsible for the anti-leukemic 
activity. 
Southam et al (unpublished) suggests that the similar structure of BEZ and fatty acids means 
BEZ can mimic high levels of fatty acid inside the cell. As a response to these ‘high levels’, 
ACC becomes inactivated causing CPTI to in-turn become more active.  
It is reasonable to believe that the increased levels of CPTI caused by PPAR activity in 
addition to the silencing of ACC resulting in increased CPTI activity would lead to an 
increased transport of fatty acids across the membrane and into the mitochondria where it 
undergoes β-oxidation. The increased fatty acid metabolism without the fatty acid content of 
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the cell being replaced would cause a disruption in the lipogenic/lipolytic balance of the cell, 
ultimately leading to apoptosis. 
4.2.4 Stearoyl-CoA Desaturase (SCDI) is decreased in BaP treated samples 
SCDI is down-regulated in BaP treated samples as shown by HL60 and GLOR western blot 
analysis, see Figure 3.7. Anti-log fold-change calculated a two-fold change in BaP treated 
samples showing BaP treated samples to express SCDI levels at half that of control groups. 
Decreased levels of SCDI lead to an increased level of saturated fatty acids (SFA) within the 
cell as they are not being converted in to monounsaturated fatty acids (MUFA) (Miyazaki and 
Ntambi, 2003). SFAs are allosteric inhibitors of ACC and although the total levels of ACC 
appear consistent across control and BaP treated samples, activity of the enzyme may differ 
between the two groups. The inhibition of ACC from accumulating SFA acts as a negative 
feedback loop for biosynthesis of fatty acids therefore regulation of the SFA:MUFA ratio by 
SCDI is crucial for the continuous production of fatty acids and lipogenesis required by 
cancerous cells to survive and proliferate (Scaglia et al., 2009). The clear down-regulation of 
SCDI in BaP treated samples results in the disruption of lipogenesis due to the decreased 
production of MUFAs. Scaglia et al suggested the down-regulation of fatty acid synthesis 
noted when SCDI activity is decreased may be a safeguard mechanism used to adapt to the 
changing cellular environment when a harmful build-up of SFA occurs (Scaglia et al., 2009). 
Much research has shown down-regulation of SCDI to cause up-regulation of PPARα target 
genes responsible for lipid oxidation whilst down-regulating genes important for lipid 
synthesis, therefore the action of BaP on SCDI also explains the changes observed in CPTI 
and FASN (enzymes that contain PPARα response elements) (Miyazaki and Ntambi, 2003). 
Furthermore, regulation of SCDI expression has been strongly linked to sterol regulatory 
element binding protein 1 (SREBP-1) (Ntambi, 1999). It has been suggested that fibrates 
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cause partial inhibition of SREBP-1 activation (König et al., 2009); therefore BEZ may be 
causing inactivation of SREBP-1 leading to a reduced expression of SCDI. It would be 
beneficial to determine levels of SREBP-1 in control and BaP treated samples to observe any 
changes. 
It may be that BaP utilises the feedback loop regulated by SCDI to disrupt the 
lipogenic/lipolytic balance. BaP may induce the down-regulation of SCDI as an initial action, 
resulting in the changes observed in CPTI and FASN, in addition to allosteric inhibition of 
ACC. The decrease in MUFA production decreases lipogenesis, whilst increased levels of 
CPTI results in higher levels of lipolysis, disrupting the healthy balance maintained by the 
cell to allow growth and proliferation, ultimately resulting in apoptosis. 
In addition, the ratio of SFA:MUFA regulated by SCDI is important for membrane 
phospholipid composition (Miyazaki and Ntambi, 2003). The down-regulation of SCDI 
caused by BaP could cause a change in the membrane composition which leads to the 
increased sensitivity to ROS observed by Southam et al (unpublished). 
4.2.5 Palmitic Acid and Oleic Acid provide rescue to BaP treated cells 
BaP clearly affects fatty acid synthesis, however it still remains unclear if this is a primary 
action or is a secondary result of something occurring elsewhere in the cell that results in the 
overall anti-leukemic activity. To determine if the inhibition of fatty acid synthesis is an 
important mode of action, fatty acid supplement experiments were performed. Complete 
rescue via supplementation should be possible if the inhibition of synthesis is one of the main 
causes for the potency of BaP in leukemic cells. 
Figure 3.11 shows that 100mM palmitic acid alone provided almost 100% rescue to HL60 
cells after 48 hours, whilst higher concentrations appeared to increase toxicity. Figure 3.12 
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illustrates the rescue activity of palmitic acid (PA), oleic acid (OA) and PA plus OA in all 
four cell lines at a much lower concentration of 25mM across a 120-hour time period.  
PA alone did not provide high levels of rescue to all cell lines when a variety of 
concentrations and time frames were tested (see Appendix I.3). Differences between the cell 
lines would account for such a difference in response to rescue via PA alone. PA produces 
palmitoyl-CoA that can either go on to produce MUFA via SCDI or it can go on to be 
transported in to the mitochondria via CPTI to undergo β-oxidation. The rate at which both of 
these occur will differ across the cell lines therefore the importance of each varies depending 
on cell metabolism of each cell line.  
If an increased level of oxidation, caused by BEZ creating a ‘high fatty acid’ environment 
within the cell, has a greater apoptotic effect than the limited production of MUFAs in HL60 
then it provides an explanation as to why PA alone gives high levels of rescue for this cell 
line and not for the others. However, all four cell lines exert similar responses to BaP 
therefore rescue via the same method should be achievable.  
The high levels of inactive ACC in addition to potential decreased ACC activity (via 
allosteric inhibition) provides limited SCDI substrates palmitoyl-CoA (16:0) and stearoyl-
CoA (18:0) due to reduced production of Malonyl-CoA. Malonyl-CoA goes on to produce 
PA, which becomes elongated to produce OA in addition to other acids which then go on to 
produce the SCDI substrates, therefore by substituting the cells with PA and OA it should 
bypass the need for Malonyl-CoA production and provide the substrates necessary for MUFA 
production thus mitigating the effect caused by lower SCDI levels.  
It is believed that BaP still causes the down-regulation of SCDI in the rescue experiments but 
because the inhibition of substrate production is overcome by substitution, the lessened 
activity of SCDI is still able to produce MUFA and increase lipogenesis. To determine SCDI 
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levels of rescued cells, protein should be extracted from post-rescue cell cultures and undergo 
western blot analysis.  
Figure 3.12 clearly shows that addition of PA alone does not always provide rescue, but the 
addition of OA does which suggests SCDI activity may play an important role in the anti-
leukemic activity of BaP. However, the combination of both PA and OA provides rescue 
across all cell lines indicative of combined SCDI and CPTI alterations caused by BaP 
resulting in apoptosis. 
OA alone provides similar rescue to the combined PA and OA supplementation for 
myelocytic cell lines HL60 and K562, whilst the Burkitt lymphoma (BL) cell lines GLOR 
and BL31 have slightly greater rescue when both fatty acids are supplemented. Notably, the 
BL lines show an overall greater level of rescue when treated with OA alone and combined 
agents when compared to myelocitic lines. This may reflect the differences in the diseases. 
The burkitts lines in vitro grow much faster than the myelocitic lines which may suggest a 
more imminent demand for both fatty acids, hence a slightly greater rescue when either one 
or both fatty acids are supplemented.  However, a more likely reason for the differences 
between the myeloid and the BL cells is that at this time point, BaP is having a more potent 
effect on the BL lines and therefore  the rescue in Burkitts lines is apparently much greater 






The combination of 5mM Bezafibrate (BEZ) and 5µM Medroxyprogesterone acetate (MPA), 
denoted as BaP, causes alterations to expression and activity of enzymes crucial for the 
maintenance of the lipogenic/lipolytic balance within leukemic cells.  The results obtained 
clearly identify the down-regulation of SCDI and FASN, whilst phosphorylated-ACC and 
CPTI are up-regulated across multiple cell lines (where n=4). These alterations in lipid 
metabolism ultimately reduce the cells ability to grow and proliferate, resulting in apoptosis. 
It is clear that BaP induces apoptosis in leukemic cell lines. FACSCalibur analysis using 
Annexin V and Propidium Iodide showed BaP induced apoptosis by >50% in both HL60 and 
K562 after 48 hours when compared to control samples.  
After 24-hours of BaP treatment alterations in lipid metabolism can be seen by western blot 
and RT-PCR analysis. SCDI expression is decreased resulting in lesser conversion of fatty 
acid substrates in to monounsaturated fatty acids (MUFA). MUFA are used for the 
production of phospholipids, triglycerides, cholesterol esters, wax esters, etc., which are 
important for the maintenance of the cell membrane fluidity. Decreased SCDI activity has 
been shown to lead to reduced expression of FASN and increased expression of CPTI as 
observed by the western blots and RT-PCR data obtained within this research. It is unknown 
if BaP acts directly on SCDI, however a regulator of SCDI expression, SREBP-1, is known to 
be inhibited by fibrates therefore it is possible that the action of BEZ of SREBP-1 is adding 
to the down-regulation of SCDI.  
Lipogenesis is inhibited by BaP treatment. Levels of phosphorylated-ACC are increased in 
BaP treated samples resulting in decreased activity of ACC therefore inhibiting the 
production of Malonyl-CoA, a key substrate for the production of fatty acids. This, combined 
with reduced FASN levels, resulting in disrupted lipid synthesis. 
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BaP increases lipolysis in leukemic cells. Malonyl-CoA is an inhibitor of CPTI, therefore the 
inactivity of ACC observed in BaP treated samples would suggest lower levels of Malonyl-
CoA therefore a heightened activity of CPTI is expected. Increased activity in combination 
with amplified CPTI levels as a response to decreased SCDI results in β-oxidation activity 
also increasing.  
Cell viability for BaP treated samples of HL60, K562, GLOR and BL31 was significantly 
increased when treatments were supplemented with a combination of the fatty acids palmitic 
acid (PA) and oleic acid (OA) at a concentration of 25mM. PA and OA alone did not provide 
rescue across all cell lines, however OA alone was more effective than PA alone. The 
combination of both was by far a more effective treatment. The substitution of PA and OA 
bypasses the need for malonyl-CoA production therefore the inhibitory action BaP exerts on 
ACC is overcome. PA can provide substrate for SCDI to produce MUFA for the creation of 
phospholipids, triglycerides, etc. or it can go on to produce substrate to be transported in to 
the mitochondria via CPTI. OA provides one of the preferred substrates for SCDI to produce 
triglycerides and cholesterol esters. The limited rescue provided by the acid agents separately 
indicates the divergent pathways that it is expected each agent rectifies is not singularly 
responsible for the anti-leukemic activity of BaP, therefore only provides partial rescue. 
Therefor it is likely that the combined action of PA and OA supplying substrate for both arms 
of the divergent pathway that causes rescue to BaP treated cells across all cell lines. 
It is reasonable to suggest the increased β-oxidation activity in addition to the decreased 
production on MUFAs caused by BaP creates an imbalance in lipogenic/lipolytic activity in 
the cell which is necessary for the growth and proliferation of cancerous cells. The effect of 
BaP across AML, CLL and lymphoma cell lines indicates this mechanism is not only 
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Appendix I – Additional Data 
AI.1: FACSCaliur Annexin V / Propidium Iodide Data (96-hour treatment) 


















AI.1 Additional data to support information shown by Figure 3.2. Annexin V and Propidium Iodide expression of HL60 





AI.2: FACSCalibur Forward / Side Scatter Data (96-hour treatment) 



















AI.2 Additional data to support information shown by Figure 3.3. Forward scatter and side scatter pattern of HL60 cells 


















AI.3 Palmitic Acid Rescue Data 
 
Figure AI.3.1 72 hour Rescue Data 
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With the ever-expanding knowledge base obtained by genome-wide studies, the importance 
and complexity of transcription has become increasingly prominent. Advanced technology in 
the form of computer analysis can now predict the presence of cis-regulatory elements; 
however these in silico systems cannot validate such predictions. Here we have shown 
transgenic zebrafish can be used as a model to test functionality of human enhancers. 
Differences in expression patterns driven by two forms of the PROX enhancer, the common 
form (PROX-G) and also its type 2 diabetes associated SNP variant counter-part (PROX-A), 
were observed. These enhancers were integrated in to the genome using a targeted integration 
system mediated by PhiC31 integrase and showed promising transmission rate, as well as 
over-coming problems associated with other transgenesis systems, most notably position 
effect. 
When examined by fluorescence microscopy,  differences in expression of the reporter in the 
pancreatic islet at 25hpf (hours post fertilisation) appears to show earlier development in 
embryos containing the enhancer with disease associated SNP variant compared to embryos 
containing the common form of the enhancer. By 30hpf, in situ analysis showed pancreatic 
islet present in both lines. This subtle difference may hint at a role in disease progression, 
however a time-course experiment would have to be performed to identify precise timings of 
development.  
The use of zebrafish as a model to elucidate enhancer function, alongside other cis-regulatory 






Diabetes is the body’s inability to regulate blood sugar levels and it is a lifelong condition. In 
the UK it affects approximately 2.9 million people, with an additional 850,000 thought to 
suffer undiagnosed diabetes (NHS, accessed May 2014). Two types of diabetes exist; 
1.1.1 Type 1 
 
Type 1 Diabetes (T1D) is an autoimmune condition that affects approximately 400,000 people 
in the UK and often develops before the age of 40. T1D is referred to as insulin-dependent as 
it is caused by the pancreas’ inability to produce insulin. Insulin is the hormone that regulates 
blood glucose levels, and if glucose levels remain too high it can cause diabetic ketoacidosis 
and damage to organs, therefore T1D sufferers receive insulin injections on a regular basis to 
achieve a healthy balanced blood glucose level (NHS, accessed May 2014). 
1.1.2 Type 2  
Type 2 Diabetes (T2D) is the most common form of the disease and accounts for 
approximately 90% of all adult diabetes sufferers. T2D is referred to as insulin-resistant as the 
pancreas either does not produce enough insulin or the body cannot use the insulin that is 
produced to perform its normal role of regulating biological processes (NHS, accessed May 
2014). 
Extensive research including numerous Genome Wide Association Studies (GWAS) have 
identified susceptibility to and progression of T2D to be linked to genetic predisposition 
(Florez et al., 2006, Groves et al., 2006, Lyssenko et al., 2007, Pomerantz et al., 2009, Fujita 
et al., 2012, Smemo et al., 2014).  
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Due to the sheer number of T2D cases in the UK alone and the surmounting evidence 
showing genetic predisposition to the disease, including changes in gene expression, research 
into genes involved in the development of T2D  must be undertaken to identify possible 
therapeutic agents.  
 
1.2 Transcription Regulates Gene Expression 
 
Spatial and temporal activation of genes are of key importance for carrying out biological 
processes, as shown by the frequent consequence of disease when dysregulation occurs 
(Maston et al., 2006). It is widely accepted that transcriptional regulatory elements play a 
functional role in the spatial and temporal expression of genes.   
Transcription is the initial phase of gene expression. Transcription is where an ‘unzipped’ 
DNA strand, known as the template strand, containing at least one gene is copied in to RNA 
by RNA Polymerase. The nucleotides of the DNA are matched with their corresponding RNA 
pair; where cytosine (C), guanine (G), thymine (T) and adenine (A) are paired with G, C, A 
and U (uracil) respectively. The transcribed RNA can ultimately relay in to a protein via 
translation, non-coding RNA genes, ribosomal RNA or transfer RNA. 
In eukaryotes, RNA Polymerase II (RNA Pol II) is responsible for the transcription of 
protein-encoding genes. There are two bodies of cis-regulatory elements (CREs) that ensure 
transcription is controlled. Firstly, a body of promoters composed of a core promoter and 
proximal promoter elements located upstream; and secondly, distal regulatory regions 




Figure 1.1: Typical Mammalian Gene Regulatory Region 
 
Figure 1.1: Schematic of a typical gene regulatory region. Figure reproduced from Maston et al, 2006. The 
core promoter and proximal promoter elements characteristically span less than 1 kb from the target gene. Distal 
regulatory elements (enhancers, silencers, insulators, and locus control regions) can be located up to 1 Mb from 
the promoter. Distal elements and core or proximal promoters may come in to contact via a mechanism that 




Core promoters (CPs) direct structural genes by encoding the time, strength, direction and 
position of transcription initiation (Yamamoto et al., 2007). CPs are often located at -30, -75 
or -90 base pairs upstream of the transcription start site (TSS) and are important for the 
assembly of the Pre-Initiation Complex (PIC), also known as the Basal Transcription 
Complex. The PIC is formed when the CP binds general transcription factors; including 
TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH, which lead to the attraction of RNA Pol II to 
the TSS site of the target gene (Maston et al., 2006). 
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Mammalian core promoters are characterised by either a T/A rich region known as the 
TATA-box or a C/G rich, largely unmethylated region known as a CpG island (Yamamoto et 
al., 2007, Deaton and Bird, 2011).  
Clusters of multiple TSSs have been shown to exist in a single promoter region, the shape of 
which can affect the profile and expression of the corresponding gene. Mammalian TATA-
promoters are described as sharp due to containing a chief TSS cluster that directs tissue-
specific expression. CpG associated promoters often exist in TATA-less regions and express 
ubiquitously with broad TSS-clusters. Such activity describes a differentiated and 
complementary role between mammalian TATA-box and CpG-island promoter regions 




Transcription of heterologous human genes containing promoters are actively increased by the 
activity of enhancers. Enhancers regulate in a spatial or temporal specific manner and are 
highly dynamic during development. They can regulate transcription of specific genes 
independent of proximity to or orientation in relation to the corresponding promoter. 
Approximately 12-21% of enhancers appear to miss non-expressed neighbouring genes in 
order to regulate more distal genes, whilst the other 79-88% of enhancers regulate 
neighbouring genes, suggestive of CREs organised locally in domains supported by 
chromosomal domains, insulator binding and genome evolution (Maston et al., 2006, Kvon et 
al., 2014).  
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Distinct enhancer elements can act on a promoter at different times, in different tissue and as a 
result of various stimuli. They comprise a cluster of transcription factor binding sites whereby 
spatial organisation and orientation regulate the enhanced transcription activity.  
The role of the enhancer appears to cross-over with the functional role of proximal promoter 
elements, however a distinctive difference is the enhancers ability to exert functional activity 
when located distally from the core promoter; including upstream or downstream of the 
promoter, in an intron or beyond the 3’ end of the gene (Maston et al., 2006). For example, 
the enhancer element that drives sonic hedgehog (Shh) expression is located 1Mb away from 
the target gene (Lettice et al., 2003).   
A favoured understanding of distal enhancer activity is that of the DNA-looping model. It is 
believed that the ‘looping out’ of DNA brings the enhancer and promoter in to close 
proximity allowing the enhancer to act upon the promoter to increase transcription activity, as 




Silencing and repression of gene expression can occur due to negative regulation of 
transcription of the target genes by silencers.  Silencers are sequence-specific elements that 
typically function individually from distance and orientation to the promoter, much like 
enhancer elements. The location of silencers can vary as they have been found to be situated 
as part of a proximal promoter or distal enhancer, but have also been identified as a separate 
distal regulatory module. 
Silencers bind repressors and co-repressors which are negative transcription factors. There are 
multiple mechanisms of action that repressors can take to exert silencing activity. In some 
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cases, they act as inhibitors and block activator binding or compete for the same site. In other 
cases, repressors have been shown to establish a repressive chromatin structure via histone 
modification or chromatin stabilizing factors, preventing activator and/or general transcription 
factor binding (Maston et al., 2006). 
1.3 Regulatory Elements in Disease Associated Disorders 
 
As previously described, execution of biological processes requires exquisite control of 
transcription for the correct expression of target genes. Mutations in key CREs can result in 
aberrations of transcriptional control which are often linked to disease.  
There are many examples of cancers caused by irregular linkages between 
enhancers/promoters and oncogenes which are a result of chromosomal translocations. The 
linkages result in changed expression of the oncogenic protein. A clear example of this is the 
multifaceted oncogene c-Myc which plays a causal role in Burkitts lymphoma (BL). c-Myc is 
over expressed in BL due to its translocation under promoter regions of heavy or light chain 
immunoglobulin genes (Miller et al., 2012). 
Another example is the case of β-thalassemia where a mutation in the core promoter 
(affecting the TATA, CACCC and EKLF binding regions) results in disrupted expression of 
the HBB gene (Epstein, 2009). These examples represent clearly the effect dysregulation of 







Table 1.1: Disease associated cis-regulatory elements 
Table 1.1 reproduced from Epstein, 2000. 
1.4 Single Nucleotide Polymorphisms 
 
In many human diseases it is the increased susceptibility to a disease or developed disease 
progression caused by complex interactions of numerous genes and variations that lead to its 
success as opposed to a single mutation on a singular gene. 
Present in the human genome at approximately every 1000bp, the most common type of 
genetic predisposition to diseases are allele variations known as single nucleotide 
polymorphisms (SNPs). SNPs can be found in coding and noncoding regions, however 93-
96% of variations identified via genome wide association studies (GWAS) have existed in 
non-coding regions thought to be in non-coding CREs such as enhancers  (Maston et al., 
2006, Corradin et al., 2014). 
77% of 349 human cell types showed GWAS SNPs to be located in open chromatin when 
analysed via epigenomic profiling, specifically DNase I hypersensitivity site profiling. These 
open chromatin sites are thought to contain enhancer elements (Maurano et al., 2012, 
Corradin et al., 2014) . Furthermore, in recent years GWAS SNPs have revealed a relationship 
with H3K4me1, H3K27ac, and H3K4me3 marked enhancer elements in relevant disease 
associated cell types (Ernst et al., 2011, Akhtar-Zaidi et al., 2012, Trynka et al., 2013, 
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Corradin et al., 2014). Research in to functional CREs in the human genome has obvious 
implications for potential future therapeutic targets. 
1.4.1 Transcription Factor 7 like 2 (TCF7L2) 
 
TCF7L2 encodes a transcription factor involved in the Wnt signalling pathway. 
Polymorphisms in TCF7L2 have been shown to be associated with susceptibility to Type 2 
Diabetes (Florez et al., 2006). 
It was identified that SNP variants (rs12255372 G>T; rs7903146 C>T) in TCF7L2 aided the 
progression of T2D with association to impaired β-cell function but not with insulin resistance 
(Florez et al., 2006). 
Extensive research on the link between TCF7L2 SNP variants and T2D has been performed, 
identifying a strong link between the two (Florez et al., 2006, Groves et al., 2006, Lyssenko et 
al., 2007, Wang et al., 2014). 
Open chromatin regions are often a tell-tale sign of enhancer locations, and a SNP present in 
an islet specific open chromatin region in TCF7L2 showed higher enhancer activity in vitro in 
the diabetes risk allele (C>T, SNP ref rs7903146) (Gaulton et al., 2010) 
1.4.2 Prospero Homeobox 1 (PROX1) 
 
PROX1 was identified as a novel fasting glucose loci after meta-analysis of GWAS covering 
glucose and insulin related traits was performed (Hu et al., 2010).  
1.4.3 Zinc Finger AN1 Domain 3 (ZFAND3) 
ZFAND3 was identified as a potential T2D associated loci after reaching genome-wide 
significance during a meta-analysis of GWAS in an Asian population. The elucidation of the 
9 
 
role of ZFAND3 has yet to be achieved, however ZFAND6, a member of the same family, 
alongside FAH had been identified at a previously detected T2D locus. The risk allele was 
identified as rs9470794 (T>C) (Cho et al., 2012). 
1.4.4 C2 Calcium Dependent Domain Containing 4A (C2CD4A) 
C2CD4A has been linked to T2D susceptibility since 2011 after combined GWAS of East 
Asian and European populations associated C2CD4A-C2CD4B with T2D at significant 
levels, with an overall p value of 8.78x10
-14 
, with statistical relevance levels being <0.05 
(Yamauchi et al., 2010).  
 The following years saw a release of a wealth of evidence supporting the role of SNPs found 
in C2CD4A relating to susceptibility to T2D (Grarup et al., 2011, Cui et al., 2011, 
Strawbridge et al., 2011, Iwata et al., 2012). 
1.4.5 Type 2 Diabetes as a Genetic Disorder 
The definition of T2D as a genetic disease is one of debate. Although clear linkages between 
disease susceptibility and progression and genetic variation exist (as discussed above), it is the 
combination of genetic factors together with environmental factors (‘risk factors’ including 
age, obesity, diet (low fibre, high saturated fat), smoking, etc.) that are a primary cause; that 
is, even with the genetic disposition it is not necessarily guaranteed that T2D will develop 
without being exposed to certain environmental factors (Freeman and Cox, 2006, Lyssenko 
and Laakso, 2013). This is what makes T2D so challenging. 
However, the identification of T2D-associated genetic predispositions and understanding of 
how these genetic variations work allows for the identification of risk prior to development of 
the disease and therefore can result in avoidance of disease development, or alternatively 
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provide elucidation of the mechanism by which T2D progresses and relay in to specialised 
therapeutic treatment resulting in more effective treatment.  
1.5 Zebrafish as a Model Organism 
Zebrafish (Danio rerio) is a fast increasing model for an array of research, with an estimated 
number of zebrafish used in research reaching far in to the millions (Reed and Jennings, 
2010). 
1.5.1 Zebrafish in Research 
Zebrafish are often used for early stage embryonic studies due to embryogenesis in zebrafish 
being similar to higher vertebrates whilst the embryos develop externally in a transparent 
chorion. The embryos remain transparent for the first few days allowing visual analysis of 
early development processes easily in vivo. Additionally, high fecundity (pairs can lay ~200-
300 eggs per week) and fast development make them an ideal model for genetic analysis 
(Dooley and Zon, 2000). 
Furthermore, with the completion of the zebrafish genome-sequencing project it was possible 
to identify that 70% of human genes have at least 1 recognizable orthologue in zebrafish. It 
was shown that 84% of human disease causing genes can be found in zebrafish, identifying 
them as a useful model for human genetic disorder studies (Howe et al., 2013). 
1.5.2 Zebrafish as a model for consolidating putative enhancers related to T2D, 
Preliminary Data 
 
Irene Miguel-Escalada (PhD student, Müller research laboratory, University of Birmingham 
Medical School) proposed the use of transgenic zebrafish embryo as a model to elucidate 
functionality of putative pancreatic-specific human enhancers that had been identified via a 
combination of chromatin signatures, bidirectional transcription and TF binding events with 
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the aim of identifying subtle changes caused by T2D disease-associated SNP variants. 
Zebrafish are an ideal model to investigate T2D as they have a common pancreatic structure 
with humans and contain conserved expression and function of pancreas-specific transcription 
factors, including PDX1, NKX6.1, NKX2.2, FOXA2 and MAFB.  
A targeted integration system facilitated by PhiC31 integrase was used to improve the 
reliability of zebrafish transgenesis and circumvented the major issue of position effect 
variability. Using this method it was possible to identify a novel zebrafish enhancer (Roberts 
et al., 2014). 
To ensure PhiC31 integrase facilitated targeted integration in vivo, a PhiC31 plasmid 
containing an attB site was inserted in to an attP site in zebrafish and was detected by reporter 
activity in lens. To do this, PhiC31 mRNA transcribed in vitro was co-injected with attB-
mCherry construct in to single cell embryos from the Tol2-based transgenic recipient line 
Tg(Xla.crygc:attP-GFP).  
Tol2 in an active autonomous vertebrate transposon isolated 
from the fish Orzyias latipes which does not require co-
injection of plasmid with transposase mRNA. These qualities 
mean introduction of Tol2 is less toxic therefore results in 
higher viability of transgenic embryos compared to other 
methods (Hamlet et al., 2006, Roberts et al., 2014). However, 
it has been observed that Tol2 does not have a target site of 
preference therefore can often lead to random integration 
(Hamlet et al., 2006). 
Figure 1.2: Reproduced from 
http://www.systembio.com/phic31 
Figure 1.2: PhiC31 Integrase  
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The use of PhiC31 can limit this random integration when used in combination with Tol2 by 
the use of the attP docking site in the genome and the attB site of the targeted plasmid (see 
Figure 1.2). 
The addition of fluorescent reporter markers means that screening for desired site-specific 
integration can be performed and eliminates confusion with integrations at pseudo attP sites. 
Roberts et al (2014) found that 66.7% of normal developing larvae were positive for mCherry 
expression when co-injected with PhiC31 mRNA and targeting construct  
pJET-attBmCherry (n=258). Comparatively, of embryos injected with the same targeting 
construct minus PhiC31 integrase, 0% were positive for mCherry expression in the lens 
(n=302); see Figure 1.3B. These results suggest the lens colour change is due to integrase-
mediated recombination events at docking sites in the recipient transgenic locus. PCR 
amplification and sequencing of the attL and attR sites that result from attP and attB site 
recombination was used to confirm integrase-dependent transgene integration (Roberts et al., 
2014), see Figure1.3A,C. 
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Figure 1.3: PhiC31 mediated integration for creation of transgenic zebrafish lines
 
Following the successful identification of targeted PhiC31 integrase mediated integration, the 
following constructs were created using PhiC31 technology; 
Table 1.2: Constructs containing T2D-associated putative enhancers 
Gene Transgenic Line Common/SNP 
PROX1 Tg(ycry-ATTR-mCherry,Hs.PROX1-G-prox1:YFP:ATTR-GFP) Common 
PROX1 Tg(ycry-ATTR-mCherry,Hs.PROX1-A-prox1:YFP-ATTR-GFP) Rare SNP Variant 
C2CD4A Tg(ycry-ATTR-mCherry,Hs.C2CD4A-C-hsp70:YFP-ATTR) Common 
C2CD4A Tg(ycry:ATTR-mCherry,Hs.C2CD4A-T-hsp70:YFP-ATTR) Rare SNP Variant 
ZFAND3 Tg(cry:ATTR-mCherry,Hs.ZFAND3-C-hsp70:YFP-ATTR-GFP) Common 
ZFAND3 Tg(cry:ATTR-mCherry,Hs.ZFAND3-T-hsp70:YFP-ATTR-GFP) Rare SNP Variant 
TCF7L2 Tg(cry:ATTR-mCherry,Hs.TCF7L2-C-tcf7l2:YFP-ATTR) Common 
TCF7L2 Tg(cry:ATTR-mCherry,Hs.TCF7L2-T-tcf7l2:YFP-ATTR) Rare SNP Variant 
*Rare SNP variants produced via site directed mutagenesis 
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The constructs were microinjected in to wild-type zebrafish embryos at 10 minutes post 
fertilisation. The embryos were screened daily for up to 5dpf, by which point red lens should 
have been visible for those with successful integration of the transgene. Those expressing red 
lens (‘founders’) were grown to maturity (F0 generation) with the aim to analyse F1 
generation expression. 
1.6 Aims and Objectives 
 
Advancements in genome-wide research and biotechnological capabilities have allowed a 
much improved identification system of potential CREs such as enhancers. However, these in 
silico systems cannot fully characterise the CREs or the effect of variations in disease 
susceptibility and progression, therefore an in vivo model is essential for validation. Zebrafish 
has great potential for such validation studies. The aim of this study is to utilise the zebrafish 
model to determine the role of putative enhancers in T2D disease progression. Stable 
transgenic zebrafish lines containing common or rare SNP variants of T2D associated putative 
enhancers attached to fluorescent markers will be crossed and fluorescent transgenic 
expression patterns will be compared and analysed. Any variation in expression observed 
between the common and disease-associated SNP could elucidate mechanisms by which T2D 




2. MATERIALS AND METHODS 
 
2.1 Materials 
All materials used were of a certified molecular biology grade. 
List adapted from Irene Migeul-Escalada PhD thesis. 
2.1.1 Antibiotics 
 
Gentamycin   BPE918-1  Fisher Bioreagents, UK 
2.1.2 Chemical Reagents 
 
Agarose  BIO-41025  Bioline Ltd., UK  
5-Bromo 4-chloro 3 indolyl 
phosphate (BCIP)  
11383221001  Roche Diagnostics, UK  
dNTPs 10mM  R0192  Thermo Scientific, UK  
Ethyl 3-aminobenzoate 
methanesulfonate 98% (MESAB)  
E10521  Sigma-Aldrich, UK  
Fetal Bovine Serum Heat Inactivated  A11-104  PAA Cell Culture, UK  
Formamide (deonized) AM9342 Ambion, UK 
Gel Loading Dye, Blue 6X  B7021S  NEB, UK  
Glycerol  G6279  Sigma-Aldrich, UK  
Heparin sodium salt  H3393  Sigma-Aldrich, UK  
N-Phenylthiourea Grade I (PTU)  P7629  Sigma-Aldrich, UK  
Nitro blue tetrazolium (NBT)  11383213001  Roche Diagnostics, UK  
Paraformaldehyde  P6148  Sigma-Aldrich, UK  
SSC buffer substance  85639  Sigma-Aldrich, UK  
Sheep serum  013000121  Interchim SA  
Tween-20  P1379  Sigma-Aldrich, UK  




Graduated Pasteur Pipette, 3ml E1414-0300 Star Lab Group 
Needle hypodermic regular bevel sterile 19G x 
25mm  
12379179  Fisher Scientific, UK  




Protinase K Sigma Life Science 39450-01-6 






DIG RNA Labelling Kit (SP6/T7) Roche 11 175 025 910 
 
2.1.6 Buffers and Solutions 
 E3 Medium: 0.5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4.  
 4% Paraformaldehyde (PFA): PFA dissolved in sterile PBS at 60° with constant stirring.  
 PBST: PBS, 0.1% Tween-20.  
 WISH Blocking Solution: 1x PBST, 2% sheep serum (v/v), 2 mg/ml BSA  
 WISH Hybridization Buffer (+):50% deionized formamide, 5X SSC, 0.1% Tween-20, 50 
μg/ml of heparin bile salts, 500 μg/ml of extensively extracted RNase-free tRNA adjusted 
to pH 6.0 by adding citric acid (460 μl of 1 M citric acid solution per 50 ml of 
hybridization buffer).  
 WISH Hybridization Buffer (-):50% deionized formamide, 5X SSC, 0.1% Tween-20  
 WISH Staining Buffer: 1 M Tris-HCl, adjusted to pH9.5, 50 mM MgCl2, 100 mM NaCl, 
0.1% Tween-20.  
 WISH Staining Solution: Dilute 225 μl of 50 mg/ml NBT and 175μl of 50 mg/ml BCIP 
with 50 ml of WISH Staining Buffer (Light sensitive).  
 WISH Stop solution: PBS pH 5.5, 1 mM EDTA, 0.1% Tween-20.  
 Antibody staining blocking buffer: 10% NBCS in PBST. 
 
2.1.7 Equipment 
Digital microINJECTOR System  MINJ-1  Tritech Research, US  
Incubator  Heraeus, Germany 
Leica TCS LSI zoom confocal 
microscope  
LSI6000  Leica, UK  
NanoDrop ND-1000 
Spectophotometer  
ND-1000  NanoDrop Technologies  
Digital Sight Nikon SMZ1500 DS-Qi1Mc  
Scan^R High-Content Screening 
Station for Life Science  
scan^r  Olympus, Germany  
 
2.2 Identifying Transgenic Zebrafish 






Table 2.1: F0 Generation Transgenic Zebrafish 
Gene Transgenic Line Common/SNP 
PROX1 Tg(ycry-ATTR-mCherry,Hs.PROX1-G-prox1:YFP:ATTR-GFP) Common 
PROX1 Tg(ycry-ATTR-mCherry,Hs.PROX1-A-prox1:YFP-ATTR-GFP) Rare SNP Variant 
C2CD4A Tg(ycry-ATTR-mCherry,Hs.C2CD4A-C-hsp70:YFP-ATTR) Common 
C2CD4A Tg(ycry:ATTR-mCherry,Hs.C2CD4A-T-hsp70:YFP-ATTR) Rare SNP Variant 
ZFAND3 Tg(cry:ATTR-mCherry,Hs.ZFAND3-C-hsp70:YFP-ATTR-GFP) Common 
ZFAND3 Tg(cry:ATTR-mCherry,Hs.ZFAND3-T-hsp70:YFP-ATTR-GFP) Rare SNP Variant 
TCF7L2 Tg(cry:ATTR-mCherry,Hs.TCF7L2-C-tcf7l2:YFP-ATTR) Common 
TCF7L2 Tg(cry:ATTR-mCherry,Hs.TCF7L2-T-tcf7l2:YFP-ATTR) Rare SNP Variant 
Table 2.1: F0 generation created via microinjection. Injections comprised 15 ng/μl of high-quality plasmid 
DNA, 30 ng/μl of CFP mRNA, 15 ng/μl of PhiC31 integrase mRNA, filtered phenol red solution (0,2%) and 
nuclease-free water up to 10 μl. 
2.2.1 In-crossing Zebrafish 
To determine founders (positive for the transgene) from F0 generation, pairs of zebrafish were 
in-crossed in 1 litre crossing tanks. The pairs were placed in the crossing tanks post-feeding 
and left over-night. The tanks contained an in-lay which acted as a guard to inhibit the fish 
from eating the embryos. Lighting would commence at 8.30am which acts as a breeding 
trigger. Labels were given to each pair that had laid and the embryos were carefully collected 
in labelled 60mm petri-dishes by filtering the water from each crossing tank with a net.  
Once collected, the embryos were transferred in to medium comprising E3 buffer and 0.5% 
gentamycin which acts as a fungicide and helps protect the embryos from infection. The 
embryos were stored in an incubator at 28.5°C. After 18 hours the embryos were transferred 
in to fresh media containing E3 buffer, 0.5% gentamycin and 5% PTU to remove 
pigmentation and allow visualisation. To avoid bacterial infection PTU medium was changed 
daily and dead embryos removed. 
2.2.2 Screening F1 generation 
The constructs contain fluorescent markers which are detectable if the construct has 
successfully integrated in to the target loci. A Nikon SMZ1500 was used to detect green 
fluorescence protein (GFP) in the lens in embryos up to 4 days post fertilisation (dpf), after 
which founding embryos expressed red lens (mCherry). mCherry is 30% of the intensity of 
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GFP therefore a period of 5dpf is usually needed for a detectable level of mCherry to be 
achieved. 
After pancreas development, expression of TCF7L2 constructs, if successfully integrated, 
should express GFP in the pancreas. Variation in expression pattern between the common and 
SNP variant should then be compared. The PROX1 constructs contain GFP that should 
express in the neurons which develop from 18 somites and is also known to express in the 
pancreas and liver. Expression patterns for C2CD4A and ZFAND3 have yet to be 
characterised however differences between the common and SNP variant should still be 
possible. 
Pairs of fish that produced transgenic F1 generation were separated from those that did not 
and were kept as founders.  
The founders were later out-crossed with AB-wild type zebrafish which have a defined 
genotype. The same method for in-crossing was used to out-cross.  
2.2.3 F1 generation Image Acquisition 
PTU-treated transgenic embryos were mounted on to 1% agarose in a 96-well plate along 
with negative embryos that act as a control. 
2.2.3.1 Making 1% agarose 96-well plate 
1g Agarose was added to 100ml water and heated until clear. In a 96-well plate, 80µl agarose 
was added to each well followed by a small amount of 100% ethanol. Agarose solution has 
high surface tension; by adding ethanol the tension is reduced allowing the agarose to set 
evenly. A brass template was inserted in to the 96-well plate and the agarose allowed to set. 
The template created grooves in the agarose producing a channel in which to orient embryos 
ready for imaging. 
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2.2.3.2 Image Acquisition 
Single embryos were plated in to the 96-well plate and oriented dorsally followed by laterally. 
The embryos were imaged using the Scan^r microscope using brightfield, YFP and RFP 
filters. 
2.3 Whole-mount In Situ Hybridization (WISH) 
WISH utilises a probe containing complementary RNA to localise a specific DNA or RNA 
tissue, for this project particularly, RNA in the pancreas and neurons in zebrafish embryos. 
2.3.1 Obtaining transgenic zebrafish embryos 
The previously identified founders were in-crossed using the same method as described in 
Section 2.1.1. The embryos were collected and stored in fresh media containing E3 buffer and 
0.5% gentamycin for the first 18 hours and then transferred in to media containing E3 buffer, 
0.5% gentamycin and 5% PTU until they reached 3dpf. 
2.3.2 Fixation of embryos 
At 3dpf embryos were fixed in 4% paraformaldehyde and left at room temperature for 2 hours 
then stored at 4°C over night. The embryos were washed twice in 2ml PBS followed by 100% 
methanol and stored at -20°C until used. 
2.3.3 Permeabilization of embryos 
The in situ hybridization was performed using the Thisse protocol (Thisse and Thisse., 2008). 
Firstly, the embryos must be permeablilized to enable the successful uptake of the probe. 
2.3.3.1 Rehydration 
The embryos were stored in 100% methanol at -20°C. 100% methanol was removed and the 
following washes were performed for 3 minutes: 
1 x 75% methanol – 25% PBS 
1 x 50% methanol – 50% PBS 
1 x 25% methanol – 75% PBS 
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4 x PBT (PBS with 0.1% tween20) 
2.3.3.2 Permeabilization of embryos 
Embryos were digested with 10µg/ml proteinase K (PK) in PBT. 
Embryos 24hours in age were digested for 10 minutes whilst embryos 48hours+ were 
digested for 30 minutes. To inhibit PK, embryos were exposed to 4%PFA-PBS for 20 minutes 
then washed 5 x 5 minutes in PBT. 
2.3.3.3 Prehybridization of embryos 
Hybridization mix (HM) was made as shown in Table 2.2: 
Table 2.2: Components of Hybridization Mix (50ml)  
Reagent Volume Final Concentration 
Formamide 25.0ml 50% formamide 
20xSSC 12.5ml 5xSSC 
Heparin 5mg/ml 0.5ml 50µg/ml 
tRNA 50mg/ml 0.5ml 500µg/ml 
Tween20 50µl 0.1% 
Citric Acid 1M 0.46ml pH6 
H2O 10.99  
 
Embryos were incubated in 2ml HM for 2.5hours at 70°C with constant gentle agitation. 
2.3.3.4 Hybridization 
The HM used for prehybridization was removed and replaced with 1ml HM containing 30ng 
antisense DIG labelled RNA (probe). 
A nanodrop spectrophotometer was used to measure the background of YFP and mCherry 
probes prior to hybridization. A blank control of water was used to calibrate the 
measurements. 
The embryos were incubated with the probes at 70°C overnight with constant gentle agitation. 
2.3.3.5 Removing antisense DIG labelled RNA probes 
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A number of washes were performed in varying concentrations of HM minus tRNA and 
Heparin at 70°C for 10 minutes; 
1 x 75% HM – 25% 2xSSC 
1 x 50% HM - 50% 2xSSC 
1 x 25% HM – 75% 2xSSC 
1 x 2xSSC 
The embryos were then washed twice in 0.2xSSC at 70°C for 30 minutes followed by a series 
of washes at room temperature for 10 minutes; 
1 x 75% 0.2xSSC – 25% PBT 
1 x 50% 0.2xSSC – 50% PBT 
1 x 25% 0.2xSSC – 75% PBT 
1 x PBT 
2.3.3.6 Incubation with Antibody 
Embryos were pre-incubated with 2mg/ml BSA with 2%sheep serum in PBT for 3 hours 
before being incubated with 1 in 5000 dilution alkaline phosphatase anti DIG antibody 
overnight at 4°C with agitation. 
2.3.3.7 Removal of unbound Antibody 
The embryos were washed 6 x 15 minutes in PBT at room temperature followed by 3 x 5 
minutes in alkaline tris buffer comprising components shown in Table 2.3. 
Table 2.3: Alkaline Tris Buffer (50ml) 
Reagent Volume Final Concentration 
Tris HCl pH9.5 1M 10ml 100mM 
MgCl2 1M 5ml 50mM 
NaCl 5M 2ml 100mM 
Tween20 0.5ml 0.1% 




2.3.3.8 Labelling embryos 
Embryos were transferred in to wells of a 24 well plate and excess alkaline tris buffer was 
removed. 700µl of labelling mix (comprising 225µl NBT, 50ml Alkaline Tris Buffer, 175µl 
BCIP) was added to each well. The plate was stored in the dark whilst the reaction occurred 
and embryonic fluorescence was monitored every 15 minutes for the first 60 minutes followed 
by every 30 minutes until the reaction was complete. 
Once complete, the labelling reaction was inhibited by the removal of the labelling mix and 
washing 3 x 5 minutes in PBS pH5, EDTA 1mM. 
The embryos were stored in glycerol at 4°C until imaged. 
2.3.3.9 Imaging fixed embryos 
Fixed embryos were mounted on to a slide in glycerol and imaged using a Leica TCS LSI 
zoom confocal microscope. Embryos were imaged in such a way that a view of the liver 






3.1 Identifying Transgenic Fish Founders 
 
Figure 3.1: Transmission Rate of In-Crossed Transgenic Fish 
 
 
Transmission rate is calculated by the following equation; 
Number of transgenic pairs identified 
Total number of pairs that laid 
For the PROX-G F0 generation, 3 of 27 in-crossed pairs that laid produced an F1 generation 
expressing red lens, due to potential for transgenic offspring being caused by a single parent 
of the pair being transgenic, 3 in 27 translates in to a transmission rate of 5.56%. PROX-A 
and C2CD4A-C gave similar transmission rates of 9.52% (4/21) and 9.09% (2/11) 































produced an F1 generation expressing red lens. 0% of TCF7L2-C, TCF7L2-T, ZFAND3-C 
and ZFAND3-T expressed red lens. Crossing record can be viewed in Appendix AI.1. 








Founding zebrafish (those with F1 generation expressing red lens) were out-crossed with 
wild-type AB zebrafish to identify the transgenic members of each pair and to elucidate the 
pattern produced by a single transgenic zebrafish. Of the out-crossed zebrafish, transmission 
rate of transgenic embryos expressing red lens produced by 3 different fish with-in the same 
line were compared. To determine transmission rate with-in the line, the following equation 
was used; 
Number of transgenic embryos 
Total number of embryos laid 
 
PROX-G transmission rate with-in the line appears highly variable with a range covering 15-






































Transmission rate or C2CD4A-C was not calculated due to time constraints of the project. 
C2CD4A-T achieves a transmission rate range of 6-18.75%; falling in-line with PROX-A 
with an average of 10%. 
 



















 Figure 3.3: WISH Analysis of PROX-G and PROX-A embryos at 3dpf: A: Embryo from line containing 
PROX-G enhancer negative for PROX expression B: Embryo from line containing PROX-A enhancer negative 
for PROX expression C: Embryo from line containing PROX-A enhancer positive for PROX expression in liver 
and neurons. Arrows identify areas of interest. All embryos underwent whole-mount in situ hybridization stained 




PROX-G embryo , negative for PROX expression PROX-G embryo , negative for PROX expression 
PROX-A embryo , negative for PROX expression PROX-A embryo , negative for PROX expression 
PROX-A embryo , positive for PROX expression PROX-A embryo , positive for PROX expression 
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Figure 3.3A shows the in situ results for embryos produced by the founders identified for the 
PROX-G line. Of 50 embryos, none showed expression through in situ testing, although red 
lens fluorescence was observed in 9 of the 50 prior to in situ analysis. Absence of PTU in the 
buffer used to treat embryos from 1dpf lead to pigmentation which made visualisation of 
mCherry in the lens difficult. Figure 3.3B represents 147/170 embryos laid from 2 founding 
PROX-A pairs. Similar to the PROX-G result, no expression was observed.  
Figure 3.3C represents the remaining 23 embryos produced by PROX-A founders. These 
showed GFP expression in the liver and ubiquitous neuronal staining can also be observed. 
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Figure 3.4: Whole-mount in situ hybridization results. A: PROX-G line 1 embryo 1 negative for GFP 
expression in pancreatic islet. B: PROX-G line 1 embryo 5 positive for GFP expression in pancreatic islet. C: 
PROX-A (SNP variant) line 1 embryo 1 negative for GFP expression in pancreatic islet. D: PROX-A (SNP 
variant) line 1 embryo 2 positive for GFP expression in pancreatic islet. Ne = Neuronal expression, MS = 
Mucous Secreting Cell, PI = Pancreatic Islet. L = lateral, DP = dorsal posterior. All embryos 30hpf. 
Figure 3.4A shows the in situ results for embryos negative for pancreatic islet expression 
produced by out-crossed founders identified for the PROX-G line at 30hpf. Of 120 embryos, 
67 showed no pancreatic islet expression through in situ testing. Figure 3.4B represents the 
remaining 54 embryos from the out-crossed PROX-G. These embryos showed pancreatic islet 
expression in addition to broad neuronal pattern and mucous secreting cells. Figure 3.4C and 

























L1-E02-L-Ne L1-E02-L-PI L1-E02-L-MS 
L1-E02-DP 
L1-E02-DP-Ne L1-E02-DP-PI L1-E02-DP-MS 
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Figure 3.5: Fluorescent Expression of PROX-G and PROX-A lines at 25hpf 
Figure 3.5: A and B represent GFP expression of PROX-G (common) line at 25hpf. C and D represent GFP 
expression of PROX-A (SNP variant) line at 25hpf. First image positioned dorsally. Second image positioned 
dorsally posterior to the left. Third image positioned laterally to the left. Image 6x magnification using Scan
R
. PI 
= Pancreatic Islet.  
Pancreatic islet can be visualised by fluorescence microscopy in positive PROX-A embryos at 
25hpf. Positive PROX-G embryos do not show pancreatic islet expression at this stage. Broad 
neuronal fluorescence can be seen in both PROX-G and PROX-A lines. High levels of 







Dorsal Dorsal Lateral 
ProxG-L1-E01DH ProxG-L1-E01DP ProxG-L1-E01L 
ProxG-L1-E02DH ProxG-L1-E02DP ProxG-L1-E02L 
ProxA-L1-E01DH ProxA-L1-E01DP ProxA-L1-E01L 
ProxA-L1-E02DH ProxA-L1-E02DP ProxA-L1-E02L 
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Figure 3.6: Fluorescent Expression of PROX-G and PROX-A lines at 48hpf
Figure 3.6: A: GFP expression of positive PROX-G (common) line at 48hpf. First image embryo 1 from Line 1 
positioned dorsally anterior to the left. Second image embryo 1 from Line 1 positioned laterally anterior to the 
left. Third image embryo 2 from Line1 positioned dorsally anterior to the left. B represents GFP expression of 
positive PROX-A (SNP variant) line at 48hpf. . First image embryo 1 from Line 1 positioned dorsally anterior to 
the left. Second image embryo 3 from Line 1 positioned dorsally anterior to the left. Third image embryo 3 from 
Line1 positioned laterally anterior to the left. Image 6x magnification using Scan
R
. PI = Pancreatic Islet, Ne = 
Neuronal expression, MS = Mucous Secreting Cells. 
Pancreatic islet can clearly be identified in both PROX-G and PROX-A lines, although 
appears slightly stronger in PROX-A embryos, see arrows labelled PI. A scattered pattern of 
mucous secreting cells can be observed in addition to broad neuronal expression in both lines 
(labelled MS and Ne). High levels of background can be observed. For further images of 
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Figure 3.7: A: YFP expression of positive PROX-G (common) line at 72hpf. First image embryo 1 from Line 1 
positioned dorsally posterior to the left. Second image embryo 2 from Line 1 positioned laterally anterior to the 
left. Third image embryo 2 from Line 1 positioned dorsally anterior to the left. B represents YFP expression of 
positive PROX-A (SNP variant) line at 72hpf. . First image embryo 1 from Line 1 positioned dorsally posterior 
to the left. Second image embryo 1 from Line 1 positioned laterally. Third image embryo 2 from Line 2 
positioned dorsally posterior to the left. Image 6x magnification using Scan
R
. PI = Pancreatic Islet, Ne = 
Neuronal expression, MS = Mucous Secreting Cells. 
Pancreatic islet can clearly be identified in both PROX-G and PROX-A lines, although 
appears slightly stronger in PROX-A embryos. A scattered pattern of mucous secreting cells 
can be observed in addition to broad neuronal expression in both lines. High levels of 
background can be observed. For further images of positive and negative embryos for both 
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4.1 PhiC31 integrase facilitates targeted integration in Zebrafish model 
 
Of the PROX-G and PROX-A F1 generation analysed, all those identified as expressing GFP 
in pancreatic islet, neurons and mucous secreting cells also expressed red lens. No embryos 
were found to express red lens or GFP pattern independent of each other therefore indicative 
of successful targeted integration mediated by PhiC31 integrase.  
Average transmission rate falls between 10-20% as shown by Figures 3.1 and 3.2 which is 
comparable to the most commonly used mediator of integration, Tol2 transposon; which 
achieves an average transmission rate between 15-20% (Clark et al., 2011). However, Tol2 
mediated transgenesis often causes position effects due to allowing random integration in to 
the genome. In animal model, such as zebrafish, exogenous genes are often randomly 
integrated in chromatin. In the circumstance that gene constructs do not fulfil requirements for 
truthful gene locus activation, the result is variable expression levels and alterations in 
temporal and spatial expression patterns, known collectively as genomic position effect 
(Bonifer et al., 1996). 
The apparent ability of PhiC31 integrase to overcome position effect whilst maintaining a 
comparable transmission rate makes it a preferential integration mediator to Tol2. 
4.2 Potential differences observed between PROX-G and PROX-A lines 
 
Analysis via fluorescence microscopy and whole mount in situ hybridization did not show 
any clear significant differences between common PROX-G line and SNP variant PROX-A 
line in pancreatic islet, neuronal or mucous secreting cell expression, however, some slight 
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differences in timing of pancreatic islet expression observed hold promise for future 
elucidation.  
The founding zebrafish identified by initial in-crossing were out-crossed with wild-type AB 
zebrafish which have a defined genotype in order to eliminate potential interference in 
expression pattern in embryos.  
The neuronal expression observed in the head of the embryo is broad and mosaic making it 
difficult to identify if a pattern is present. Fluorescence analysis at 72hpf in PROX-G embryos 
showed neuronal expression more strongly when compared to PROX-A embryos of the same 
developmental stage, see Figure 3.7. However, due to time constraints of the project it 
remains unclear if these are a particular group of neurons with a specific function or if they 
cross multiple groups and obligate many functions. Without knowing the function of these 
neurons that are expressed it cannot be concluded if the difference observed between the 
common and SNP variant lines is of significant value. 
Furthermore, the staining apparent along the spinal cord of the embryos is inconsistent and 
patchy (Figure 3.7), unlike normal neuronal expression patterns. Under further analysis, it is 
believed that this expression is of mucous secreting cells as identified by Thisse et al (2001). 
Mucous secreting cells are expressed differently by each individual zebrafish therefore 
making the variation in the spinal cord expression null for the purpose of this research. 
Fluorescence microscopy of embryos at 25hpf (hours post fertilisation) (Figure 3.5) showed a 
potential difference in the timing of pancreatic islet development between PROX-G and 
PROX-A lines. At this stage in development, pancreatic islet was visible by fluorescence 
microscopy in PROX-A embryos but not visible in PROX-G lines, therefore it may be 
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plausible that the disease associated SNP variant causes an alteration in pancreas 
development. By 30hpf in situ analysis identified pancreatic islet in both lines. 
To elucidate any alterations in development of the pancreatic islet, it would be beneficial to 
monitor expression over time. By identifying the average stage at which the islet is visible via 
fluorescence for both lines, it would be possible to identify how accelerated development is as 
a result of the SNP variant. Although the initial aim of the study was to identify differing 
patterns between the lines, it may be that it is not difference in spatial expression, but actually 
the difference in temporal expression that causes T2D susceptibility associated with the SNP.  
4.3 C2CD4A enhancers may be too weak to drive the hsp70 promoter 
 
Both C2CD4A-C and CDCD4A-T lines produced F1 generation expressing red lens but no 
other expression was observed. The common C2CD4A-C line achieved a transmission rate 
9.09% (2/11 pairs produced transgenic embryos) whilst C2CD4A-T achieved a rate of 20% 
(8/20 pairs produced transgenic embryos). Further elucidation of C2CD4A-T founders 
identified a range of 6-18% transmission rate across 2 lines. The design of the constructs 
allows gamma crystalline (ɣ-Cry) to drive expression of mCherry whilst downstream the 
putative enhancer acts on the promoter to drive gene expression (Figure 1.3A). The construct 
must be successfully integrated for expression to occur therefore mCherry expression in the 
lens identifies that integration has been accomplished. The observed lack of GFP/YFP 
expression suggests that the enhancers, which comprise a cluster of transcription factor 
binding sites, fail to attract transcription factors to the promoter to a high enough level 
resulting in failed transcription and therefore lack of gene expression. 
Alternatively, GFP/YFP expression may be so low that it cannot be detected by the low 
sensitivity of fluorescence imaging. Whole-mount In Situ Hybridization (WISH) analysis 
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presents a solution to this issue. Embryos fixed at the developmental stage of interest can be 
exposed to a probe containing complementary RNA to localise specific RNA in pancreatic 
islet and neurons. WISH provides a more sensitive method for enhancer activity and so 
provides an alternative method of analysis for zebrafish with weak enhancer driven 
expression. 
4.4 ZFAND3 and TCF7L2 lines did not produce transgenic F1 generation 
 
Of the 18 and 13 pairs that laid for ZFAND3-C (Z.C) and ZFAND3-T (Z.T) respectively, no 
transgenic embryos were produced. With 10-20% transmission rate appearing for other lines, 
at least 1 transgenic pair from each line was expected, or alternatively an approximate 
expectation of 170 and 100 transgenic embryos for the corresponding 1720 (Z.C) and 1060 
(Z.T) embryos screened.  
For TCF7L2 lines, lower numbers of embryos were screened. In total, 13 pairs laid from the 
TCF7L2 lines (6 and 7 for TCF7L2-C and TCF7L2-T respectively) therefore it would be 
expected that at least one of the pairs would produce transgenic F1 generation. A total of 870 
embryos (450 and 420 for TCF7L2-C and TCF7L2-T respectively) would result in an 
expected 80 transgenic embryos to have been observed. 
A reason for failed expression may be due to single-copy integration at the docking site. A 
single copy integration site, namely Xla.crygc:attP-GFP, was specifically achieved for the 
recipient transgenic lines so that a stable, reproducible and single standardized landing site 
was attained. The lab identified a line (uobL6) that contained a single copy of this integration 
site therefore uobL6 was chosen for the creation of the enhancer-containing lines used 
throughout this project. Additionally, the enhancers may not work in the genomic context of 
uobL6. To overcome these issues the multi-copy line designated uobL12 could be used. 
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Southern blot analysis of uobL12 performed by Irene Miguel-Escalada identified integration 
of the desired transgene (Xla.crygc:attP-GFP integration site) with an approximate copy 
number of 11.6.  
Alternatively, a technical problem at the establishment of transgenesis may otherwise be the 
cause for the apparent negative result for this line. However, as all other variables remain 
consistent and only the enhancer sequence differs between all of the lines created; there is no 
obvious technical cause for lesser efficiency of targeted recombination. 
Finally, considering the low number of zebrafish screened for TCF7L2 lines, it may be 
possible that negative selection has occurred and so by chance only non-transgenic zebrafish 
have been crossed, thus in the event of more zebrafish being screened transgenic founders 
may be identified. 
4.5 Time-constraints hindered project progression 
 
As is the nature of working with animals, some activity is unpredictable. With this project it 
was not always possible to obtain embryos when crosses were set-up. In the process of 
identifying founders, as many crosses as possible were set up, however on average only 50% 
of the pairs produced embryos. For example, 55 pairs of PROX-G were in-crossed with only 
27 producing embryos. Of those 27 pairs, only 3 zebrafish have been identified as transgenic 
(positive for red lens and pancreatic islet expression). For PROX-A, 44 pairs were in-crossed 
and only 21 pairs laid, resulting in 4 transgenic zebrafish being recognized. The PROX lines 
were the most mature of the F0 generation transgenic lines and so these zebrafish were 




A summary of the other lines laying record is as follows; C2CD4A-C line had a total of 22 
pairs set-up with only 11 producing embryos. Of these 11 pairs, 2 transgenic zebrafish have 
been identified. C2CD4A-T line had a total of 33 pairs set-up with 20 producing embryos. Of 
these 20 pairs, 8 zebrafish have been identified as transgenic. ZFAND3-C had 18/26 pairs 
produce embryos and ZFAND3-T 13/21 with no transgenic zebrafish positive for red lens 
expression identified. Finally, 6/23 and 7/12 pairs laid for TCF7L2-C and TCF7L2-T 
respectively again resulting in no transgenic zebrafish positive for red lens expression, see 
crossing record in Appendix AI.1 for further details. 
With only 50% of crosses set up producing embryos, it leaves many zebrafish unscreened. In 
addition to this, due to the sheer number of F0 generation it was not possible to cross all of the 
available zebrafish for each line therefore opportunity for identifying transgenic zebrafish has 
been missed. 
Moreover, once the zebrafish have been crossed, they are kept in breeding tanks for up to 5 
days until embryos have been screened for red lens. Once the transgenic F1 generation has 
been identified, the founding zebrafish were separated from the negative zebrafish ready to be 
out-crossed with wild-type AB. Having been recently crossed and kept in a 1 litre breeding 
tank for 5 days, the zebrafish take 7 days to recover and therefore cannot be crossed again in 
this time, resulting in a week-long delay before out-crossing can begin. Once again, when out-
crossed there is no guarantee that all of the zebrafish will lay and therefore to obtain a 
minimum of 3 transgenic lines for each construct to be compared via fluorescence microscopy 
is extremely time consuming and success is unpredictable.  
The difficulties and delays in obtaining embryos for positively identified transgenic zebrafish 
for each line resulted in insufficient numbers obtained and time available for the attempt to 
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quantify potential difference between PROX-G and PROX-A variant activity in WISH or 
fluorescence data. A minimum of 3 lines (3 transgenic zebrafish) for each variant is required 
for comparison to detect the degree of variation of activity between lines of the same 
construct versus variation between lines with different constructs. 
 
4.6 Outstanding Aims 
 
It would be beneficial to screen the remaining un-crossed zebrafish for each F0 transgenic line 
in order to fully elucidate transgenic potential. Further identification of transgenic zebrafish 
positive for red lens for PROX and C2CD4A lines will provide a solid platform for the 
identification of any potential differences in spatial and temporal expression that may occur 
between the common and SNP variant lines. 
Furthermore, complete screening of TCF7L2 lines will eliminate the possibility of negative 
selection and identify if integration has been successful or unsuccessful. If successful, 
analysis of spatial and temporal differences can be obtained as with PROX and C2CD4A 
lines. If integration is found to be unsuccessful, it may be possible to use mutli-copy line 
uobL12 as opposed to single-copy uobL6 to create transgenic lines for TCF7L2 and 
ZFAND3.  
Potential differences in temporal expression can be observed in pancreatic islet at 25hpf, see 
Figure 3.5. Visual analysis identifies expression of pancreatic islet in PROX-A (SNP variant) 
embryos but not in PROX-G (common) embryos. This difference at such an early stage in 
development suggests the SNP may cause alteration in the timing of pancreas development, 
which in turn may be linked to T2D susceptibility and progression associated with the SNP. A 
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time-course of fluorescence images should be captured in order to identify the developmental 
stage that pancreatic islet develops in both PROX-G and PROX-A lines to determine the 
magnitude of change in temporal expression appearing to be caused by the T2D-associated 
SNP. A minimum of 3 replicates would be required to support reliability of timing results. 
Similarly, potential differences in intensity of expression can be observed in pancreatic islet at 
72hpf (see Figure 3.7), whereby intensity of pancreatic islet expression in PROX-A lines 
appear comparatively stronger than in PROX-G lines. To quantify this difference, it would be 
possible to perform densitometry analysis on fluorescence images using ImageJ software. As 
a control, the same analysis could be performed on embryos negative for pancreatic islet 
expression. The results of densitometry would give a numeric value for controls that are 
negative for pancreatic islet expression therefore providing a result for ‘background’, whilst 
providing numeric value for expression in positive embryos. These numeric values can be 
used to quantify the magnitude of difference between pancreatic islet expression in both 
common and SNP lines. Again, a minimum of 3 replicates (from 3 founding zebrafish) would 
be needed to ensure magnitude of change is representative of the entire transgenic line as 
opposed to singularly representative of that embryo or founding zebrafish. 
An observable change in expression patterns between the PROX common and SNP variant 
lines is not obvious from the experiments undertaken within this project to date. However, at 
72hpf, fluorescence imaging identified a slightly more defined neuronal pattern in PROX-G 
embryos. Due to the difficulty in getting zebrafish to lay and the time it takes to image the 
embryos, only embryos from one pair of PROX-G zebrafish positive for red lens were 
imaged, therefore it is not conclusive if the neuronal expression is singular to the founding 





The use of zebrafish as an in vivo validation tool for putative enhancers remains unconfirmed 
but provides promising results thus far. Enhancer elements in the PROX lines clearly drive 
expression in pancreatic islet, neurons and mucous secreting cells. Although no discerning 
pattern between common and SNP variant lines has been observed in this project, it may not 
be spatial expression that is altered but perhaps alterations to temporal activity as indicated by 
the noticeable difference of pancreatic islet expression by fluorescence microscopy at 25hpf. 
It appears as though GPF is expressed in the pancreatic islet by the SNP variant line, PROX-
A, whilst is much weaker in the common PROX-G line at 25hpf. By 48hpf, both lines express 
pancreatic islet, however expression appears slightly stronger in PROX-A embryos, followed 
at 72hpf by a similar pattern. Elucidation of this difference in expression could be achieved by 
monitoring reporter expression over time. 
Time constraints prevented the complete screening of all lines therefore transgenic zebrafish 
are likely to have been missed. This task should be completed in order to identify all 
transgenic zebrafish for PROX and C2CD4A lines, as well as any eventual ZFAND3 or 
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APPENDIX I – ADDITIONAL DATA 
  
AI.1.   Crossing Record
No. Pairs 
that laid
Tg(ycry-ATTR-mCherry,Hs.PROX1-G-prox1:YFP:ATTR-GFP) Common _G P.G 30/03/2014 11/23 P.G 1 25 0
P.G 2 120 0
P.G 3 30 0
P.G 4 50 17 RL+GL 
P.G 5 100 0
P.G 6 40 0
P.G 7 100 0
P.G 8 50 0
P.G 9 30 0
P.G 10 50 0
P.G 11 70 0
11/06/2014 1/12 P.G 1 50 0
01/07/2014 15/20 P.G 1 200 0
P.G 2 120 0
P.G 3 150 0
P.G 4 150 0
P.G 5 50 0
P.G 6 100 0
P.G 7 200 65 RL
P.G 8 70 0
P.G 9 100 0
P.G 10 100 19 RL
P.G 11 70 0
P.G 12 50 0
P.G 13 50 0
P.G 14 60 0
P.G 15 60 0
Tg(ycry-ATTR-mCherry,Hs.PROX1-A-prox1:YFP-ATTR-GFP) Rare Variant _AP.A 07/04/2014 18/28 P.A 1 30 0
P.A 2 40 0
P.A 3 20 0
P.A 4 20 0
P.A 5 50 0
P.A 6 60 0
P.A 7 30 0
P.A 8 20 0
P.A 9 70 0
P.A 10 10 0
P.A 11 100 0
P.A 12 80 1 RL, 1 RL+GL
P.A 13 50 1 RL, 3 RL+GL
P.A 14 10 0
P.A 15 50 0
P.A 16 10 0
P.A 17 40 1 RL, 10 RL+GL
P.A 18 30 2 RL+GL, 2 WRL
11/06/2014 3/16 P.A 1 120 0
P.A 2 50 0
P.A 3 60 0
Tg(ycry-ATTR-mCherry,Hs.C2CD4A-C-hsp70:YFP-ATTR) Common _ C C.C 26/03/2014 11/22 C.C 1 50 0
C.C 2 20 0
C.C 3 25 0
C.C 4 80 50 RL 
C.C 5 40 0
C.C 6 40 0
C.C 7 30 4 RL 
C.C 8 70 0
C.C 9 50 0
C.C 10 60 0
C.C 11 50 0
Tg(ycry:ATTR-mCherry,Hs.C2CD4A-T-hsp70:YFP-ATTR) Rare Variant  _TC.T 01/01/2014 20/33 C.T 1 50 1 RL, 1RL+GL 
C.T 2 15 0
C.T 3 20 0
C.T 4 50 1 RL 
C.T 5 80 0
C.T 6 20 5 RL, 6 RL+GL 
C.T 7 60 0
C.T 8 90 0
C.T 9 40 0








Label Date Crossed Pair
C.T 11 60 1 RL 
C.T 12 30 0
C.T 13 30 0
C.T 14 40 3 RL, 4 RL + GL 
C.T 15 20 0
C.T 16 20 1 RL, 1RL+GL 
C.T 17 30 0
C.T 18 50 0
C.T 19 40 4 RL, 1 RL+GL 
C.T 20 20 3 RL, 2 RL+GL 
Tg(cry:ATTR-mCherry,Hs.ZFAND3-C-hsp70:YFP-ATTR-GFP) Common _C Z.C 09/04/2014 6/23 Z.C 1 100 0
Z.C 2 50 0
Z.C 3 100 0
Z.C 4 30 0
Z.C 5 60 0
Z.C 6 60 0
13/07/2014 13/20 Z.C 7 100 0
Z.C 8 300 0
Z.C 9 100 0
Z.C 10 60 0
Z.C 11 80 0
Z.C 12 50 0
Z.C 13 40 0
Z.C 14 70 0
Z.C 15 200 0
Z.C 16 70 0
Z.C 17 100 0
Z.C 18 50 0
Z.C 19 100 0
cry:ATTR-mCherry,Hs.ZFAND3-T-hsp70:YFP-ATTR- Rare Variant _TZ.T 09/04/2014 2/6 Z.T 1 50 0
Z.T 2 30 0
13/07/2014 11/15 Z.T 3 50 0
Z.T 4 80 0
Z.T 5 90 0
Z.T 6 60 0
Z.T 7 60 0
Z.T 8 60 0
Z.T 9 50 0
Z.T 10 100 0
Z.T 11 200 0
Z.T 12 80 0
Z.T 13 150 0
Tg(cry:ATTR-mCherry,Hs.TCF7L2-C-tcf7l2:YFP-ATTR Common  _C T.C 24/03/2013 3/6 T.C 1 100 0
T.C 2 40 0
T.C 3 50 0
23/06/2014 2/11 T.C 1 50 0
T.C 2 180 0
15/07/2014 13/20 T.C 1 100 0
T.C 2 300 0
T.C 3 100 0
T.C 4 60 0
T.C 5 50 0
T.C 6 50 0
T.C 7 80 0
T.C 8 70 0
T.C 9 200 0
T.C 10 70 0
T.C 11 100 0
T.C 12 50 0
T.C 13 80 0
Tg(cry:ATTR-mCherry,Hs.TCF7L2-T-tcf7l2:YFP-ATTR) Rare Variant _TT.T 23/06/2014 3/11 T.C 1 200 0
T.C 2 100 0
T.C 3 150 0
15/07/2014 11/15 T.C 1 50 0
T.C 2 80 0
T.C 3 40 0
T.C 4 60 0
T.C 5 60 0
T.C 6 60 0
T.C 7 50 0
T.C 8 100 0
T.C 9 200 0
T.C 10 80 0






AI.2 48hpf FLUORESCENCE IMAGES 































AI.3 72hpf FLUORESCENCE IMAGES 
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